

Fibrosis stage is the strongest predictor for diseaseâ€™sp
33 years of followâ€™up

Hepatology

61, 1547-1554

DOI: [10.1002/hep.27368](https://doi.org/10.1002/hep.27368)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. <i>Gastroenterology</i> , 2015, 149, 1305-1308.	0.6	51
2	Nonalcoholic fatty liver disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15080.	18.1	612
3	Cardiovascular diseases after liver transplantationâ€”a still emerging and unsolved problem!. <i>Liver Transplantation</i> , 2015, 21, 870-872.	1.3	3
4	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 1149-1153.	0.8	21
5	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. <i>World Journal of Gastroenterology</i> , 2015, 21, 11077.	1.4	132
6	Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance. <i>Nutrients</i> , 2015, 7, 9127-9138.	1.7	117
7	Vitamin D: A new player in non-alcoholic fatty liver disease?. <i>World Journal of Gastroenterology</i> , 2015, 21, 1718.	1.4	125
8	Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease. <i>PLoS ONE</i> , 2015, 10, e0127991.	1.1	261
9	Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis. <i>PLoS ONE</i> , 2015, 10, e0128774.	1.1	59
10	Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	70
11	Nonalcoholic Fatty Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2263.	3.8	1,810
12	Association Between Sex-Specific Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Chinese Adults. <i>Medicine (United States)</i> , 2015, 94, e802.	0.4	50
14	Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis. <i>Hepatology</i> , 2015, 61, 1462-1464.	3.6	22
15	Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a dietâ€”induced mouse model of nonalcoholic fatty liver disease. <i>Molecular Nutrition and Food Research</i> , 2015, 59, 879-893.	1.5	102
16	Non-alcoholic fatty liver â€” Perhaps not so benign. <i>Journal of Hepatology</i> , 2015, 62, 1002-1004.	1.8	38
17	Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , 2015, 241, 145-150.	0.4	60
18	Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1243-1245.	1.4	23
19	Weight Loss for a Healthy Liver. <i>Gastroenterology</i> , 2015, 149, 274-278.	0.6	11

#	ARTICLE	IF	CITATIONS
20	Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 63, 962-970.	1.8	101
21	Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2062-2070.	2.4	267
22	Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2190-2204.	2.4	47
23	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. <i>Digestive Diseases</i> , 2015, 33, 598-607.	0.8	33
24	Cardiovascular complications of NAFLD—they do matter. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 434-436.	8.2	3
25	The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. <i>Gastroenterology</i> , 2015, 149, 278-281.	0.6	59
26	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015, 62, S65-S75.	1.8	228
27	Obesity: physiologic changes and implications for preoperative management. <i>BMC Anesthesiology</i> , 2015, 15, 97.	0.7	59
28	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 338-348.	1.8	27
29	5 α -Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. <i>Endocrinology</i> , 2015, 156, 2863-2871.	1.4	38
30	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. <i>Drugs</i> , 2015, 75, 1373-1392.	4.9	61
31	Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 203-206.	1.8	6
32	Nonalcoholic fatty liver disease — current status and future directions. <i>Journal of Digestive Diseases</i> , 2015, 16, 541-557.	0.7	80
33	Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. <i>Seminars in Liver Disease</i> , 2015, 35, 207-220.	1.8	113
34	Current and Future Burden of Chronic Nonmalignant Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2031-2041.	2.4	111
35	Caring for children with NAFLD and navigating their care into adulthood. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 617-628.	8.2	17
36	Non-alcoholic fatty liver disease. <i>Medicine</i> , 2015, 43, 585-589.	0.2	6
37	Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. <i>Gastroenterology</i> , 2015, 149, 1784-1793.	0.6	294

#	ARTICLE	IF	CITATIONS
39	Sirtuins and nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 10084.	1.4	99
40	Nonalcoholic fatty liver disease as a multi-systemic disease. <i>World Journal of Gastroenterology</i> , 2016, 22, 4079.	1.4	100
41	Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2016, 67, 286.	0.2	0
42	How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?. <i>Frontiers in Endocrinology</i> , 2016, 7, 145.	1.5	19
43	Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2016, 17, 633.	1.8	114
44	The Natural Course of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2016, 17, 774.	1.8	456
45	Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr ^{-/-} Mice Reversible?. <i>PLoS ONE</i> , 2016, 11, e0146942.	1.1	35
46	Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. <i>PLoS ONE</i> , 2016, 11, e0147804.	1.1	34
47	Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0163069.	1.1	63
48	Role of Hedgehog Signaling Pathway in NASH. <i>International Journal of Molecular Sciences</i> , 2016, 17, 857.	1.8	35
49	Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. <i>Frontiers in Pharmacology</i> , 2016, 7, 159.	1.6	67
50	Current management of NAFLD. <i>Medicine and Pharmacy Reports</i> , 2016, 89, 19-23.	0.2	19
51	Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD). , 0, , .		7
52	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , 2016, 22, 9674.	1.4	93
53	Nonalcoholic fatty liver disease - A multisystem disease?. <i>World Journal of Gastroenterology</i> , 2016, 22, 9488.	1.4	148
54	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2016, 95, e3446.	0.4	44
55	How to diagnose NAFLD in 2016. <i>Journal of Hepatology</i> , 2016, 65, 643-644.	1.8	36
56	Performance of noninvasive models of fibrosis in predicting mild to moderate fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 572-579.	1.9	38

#	ARTICLE	IF	CITATIONS
57	Factors Associated With Major Adverse Cardiovascular Events After Liver Transplantation Among a National Sample. <i>American Journal of Transplantation</i> , 2016, 16, 2684-2694.	2.6	130
58	Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. <i>Hepatology</i> , 2016, 63, 754-763.	3.6	101
59	Reply. <i>Hepatology</i> , 2016, 64, 310-311.	3.6	0
60	Screening for nonalcoholic fatty liver disease in patients with atherosclerotic coronary disease?â€”In principle yes, in practice not yet. <i>Hepatology</i> , 2016, 63, 688-690.	3.6	4
61	Male 11 ^β -HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. <i>Endocrinology</i> , 2016, 157, 3493-3504.	1.4	16
62	Noninvasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and) Tj ETQq1 1 0.784314 rgBT /Overlo	3.6	4
63	Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2016, 64, 2234-2243.	3.6	54
64	Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 63, 745-753.	3.6	63
65	Association of coronary artery calcification with liver fibrosis in <sc>Japanese</sc> patients with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2016, 46, 1107-1117.	1.8	17
66	Elevated serum ferritin is associated with increased mortality in nonalcoholic fatty liver disease after 16 years of follow-up. <i>Liver International</i> , 2016, 36, 1688-1695.	1.9	54
67	Epigenetics in liver disease: from biology to therapeutics. <i>Gut</i> , 2016, 65, 1895-1905.	6.1	115
70	Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1356-1364.	1.1	117
71	A Bugs Battle on Behalf of the Liver. <i>GE Portuguese Journal of Gastroenterology</i> , 2016, 23, 126-129.	0.3	0
72	Reduced lysosomal acid lipase activity â€” A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. <i>Digestive and Liver Disease</i> , 2016, 48, 909-913.	0.4	24
73	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. <i>Journal of Hepatology</i> , 2016, 65, 589-600.	1.8	965
74	EASLâ€”EASDâ€”EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Diabetologia</i> , 2016, 59, 1121-1140.	2.9	485
75	EASLâ€”EASDâ€”EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 1388-1402.	1.8	3,403
76	Natural History of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1226-1233.	1.1	107

#	ARTICLE	IF	CITATIONS
77	Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1365-1374.	1.1	101
78	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. <i>Obesity Facts</i> , 2016, 9, 65-90.	1.6	371
79	Morbidly obese patient with nonalcoholic steatohepatitis-related cirrhosis who died from sepsis caused by dental infection of <i>Porphyromonas gingivalis</i> : A case report. <i>Hepatology Research</i> , 2016, 46, E210-5.	1.8	9
80	Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. <i>Current Hepatology Reports</i> , 2016, 15, 117-124.	0.4	1
81	Diagnosis of non-alcoholic fatty liver disease (NAFLD). <i>Diabetologia</i> , 2016, 59, 1104-1111.	2.9	76
82	Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 65, 570-578.	1.8	300
83	Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus. <i>Clinical Diabetes and Endocrinology</i> , 2016, 2, 9.	1.3	45
84	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016, 15, 75-85.	0.4	87
85	Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2016, 15, 86-95.	0.4	23
86	Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. <i>Diabetologia</i> , 2016, 59, 1112-1120.	2.9	102
87	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016, 65, 95-102.	1.8	91
88	Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. <i>BMJ, The</i> , 2016, 354, i4428.	3.0	141
89	The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. <i>Journal of Hepatology</i> , 2016, 65, 1263-1265.	1.8	140
90	Inpatient healthcare utilisation in patients with alcoholic liver disease: what are the costs and outcomes?. <i>Internal Medicine Journal</i> , 2016, 46, 1407-1413.	0.5	4
91	Is Magnetic Resonance Imaging Really More Accurate for Classifying Steatosis Than Controlled Attenuation Parameter?. <i>Gastroenterology</i> , 2016, 151, 374-375.	0.6	7
92	Review article: emerging antifibrotic therapies in the treatment of nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1109-1123.	1.9	46
93	Obesity, NASH, and HCC. , 2016, , 275-286.		0
94	Non-alcoholic fatty liver disease in 2016. <i>British Medical Bulletin</i> , 2016, 119, 143-156.	2.7	61

#	ARTICLE	IF	CITATIONS
95	How to Diagnose Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2016, 34, 19-26.	0.8	15
96	Presence of alcoholic steatohepatitis, but no selective histological feature, indicates an increased risk of cirrhosis and premature death. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1367-1374.	0.6	5
97	Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. <i>Visceral Medicine</i> , 2016, 32, 329-334.	0.5	32
100	Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2016, 6, 33386.	1.6	220
101	Nonalcoholic fatty liver disease activity score and mortality: Imperfect but not insignificant. <i>Hepatology</i> , 2016, 64, 309-310.	3.6	2
102	Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 73-84.	3.6	7,346
103	A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2016, 64, 85-91.	3.6	128
104	The macrophage activation marker <i>CD163</i> is associated with morphological disease stages in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2016, 36, 1549-1557.	1.9	94
105	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. <i>Journal of Hepatology</i> , 2016, 65, 425-443.	1.8	366
106	Pharmacological management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1183-1195.	1.5	86
107	Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1263-1268.	0.6	21
108	Dual-5 α -Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 103-113.	1.8	50
109	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. <i>Hepatology</i> , 2016, 63, 2032-2043.	3.6	239
110	Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. <i>Journal of Hepatology</i> , 2016, 64, 1358-1364.	1.8	67
111	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Physiology</i> , 2016, 78, 181-205.	5.6	302
112	FibroGENE: A gene-based model for staging liver fibrosis. <i>Journal of Hepatology</i> , 2016, 64, 390-398.	1.8	64
113	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development—a potential therapeutic target?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 229-242.	1.4	44
114	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1811-1822.e4.	0.6	93

#	ARTICLE	IF	CITATIONS
115	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 1798-1810.	0.6	129
116	The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 677-684.	0.2	122
117	Entering the GOLDEN Age for Therapies in NASH. <i>Gastroenterology</i> , 2016, 150, 1073-1076.	0.6	4
118	High prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population?. <i>Hepatology</i> , 2016, 63, 20-22.	3.6	10
119	End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 11-13.	0.6	19
120	Histological Assessment of NAFLD. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1348-1355.	1.1	44
121	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1246-1267.	1.1	99
122	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. <i>Gastroenterology</i> , 2016, 150, 1219-1230.e6.	0.6	506
123	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and β , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5.	0.6	847
124	Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1087-1095.	1.5	53
125	Management of NAFLD: a stage-based approach. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 196-205.	8.2	287
126	Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2016, 64, 1211-1213.	1.8	21
127	Non-alcoholic fatty liver disease and liver transplantation. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1208-1223.	1.5	40
128	Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. <i>Gastroenterology</i> , 2016, 150, 1849-1862.	0.6	24
129	Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools. <i>Hepatology International</i> , 2016, 10, 448-461.	1.9	8
130	Opposite associations between alanine aminotransferase and γ -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 783-793.	1.5	20
131	Nonalcoholic Fatty Liver Disease and the Gut Microbiome. <i>Clinics in Liver Disease</i> , 2016, 20, 263-275.	1.0	73
132	A LEAN treatment for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2016, 387, 628-630.	6.3	7

#	ARTICLE	IF	CITATIONS
133	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet</i> , The, 2016, 387, 679-690.	6.3	1,397
134	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. <i>Gastroenterology</i> , 2016, 150, 145-155.e4.	0.6	201
135	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1619-1628.	2.4	47
136	Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model. <i>Digestive Diseases and Sciences</i> , 2016, 61, 137-148.	1.1	10
137	Non-alcoholic fatty liver disease and risk of cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1136-1150.	1.5	190
138	Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 905-912.	1.1	17
139	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. <i>Hepatology</i> , 2017, 65, 54-64.	3.6	260
140	Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese. <i>Obesity Surgery</i> , 2017, 27, 115-125.	1.1	30
141	Classification of patients with nonalcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. <i>Hepatology Research</i> , 2017, 47, 216-225.	1.8	37
142	Systematic review: Current evidence in nonalcoholic fatty liver disease lacks relevance to patients with advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 950-956.	1.4	5
143	Pathology of nonalcoholic fatty liver disease. <i>Liver International</i> , 2017, 37, 85-89.	1.9	247
144	Therapies in nonalcoholic steatohepatitis (NASH). <i>Liver International</i> , 2017, 37, 97-103.	1.9	188
145	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , 2017, 49, 471-483.	0.4	254
146	Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway. <i>Pharmacological Reports</i> , 2017, 69, 666-672.	1.5	29
147	Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. <i>Gut</i> , 2017, 66, 180-190.	6.1	342
148	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. <i>Hepatology</i> , 2017, 65, 1557-1565.	3.6	1,294
149	BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. <i>Scientific Reports</i> , 2017, 7, 42801.	1.6	94
150	Current and future treatment options in non-alcoholic steatohepatitis (NASH). <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 357-369.	1.4	40

#	ARTICLE	IF	CITATIONS
151	Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 288-297.	3.7	138
152	Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1453-1460.e1.	2.4	42
153	Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 379-390.	1.3	30
154	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. <i>Gastroenterology</i> , 2017, 153, 53-55.e7.	0.6	51
155	Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. <i>Lipids in Health and Disease</i> , 2017, 16, 46.	1.2	19
156	Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. <i>Liver International</i> , 2017, 37, 1389-1396.	1.9	44
157	Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. <i>JAMA Internal Medicine</i> , 2017, 177, 633.	2.6	339
158	Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 371-382.	1.4	37
159	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017, 66, 1688-1696.	6.1	59
160	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , 2017, 66, 1321-1328.	6.1	172
161	Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: The CARDIA study. <i>Obesity</i> , 2017, 25, 642-651.	1.5	37
162	JPEN Journal Club 25. Study Design. <i>Journal of Parenteral and Enteral Nutrition</i> , 2017, 41, 263-265.	1.3	0
163	Liver fibrosis scores predict liver disease mortality in the United States population. <i>Hepatology</i> , 2017, 66, 84-95.	3.6	158
164	Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. <i>American Journal of Gastroenterology</i> , 2017, 112, 581-587.	0.2	178
165	Hepatic steatosis, steatohepatitis, and chemotherapy-related liver injury. , 2017, , 1065-1072.e3.		0
166	Lipid droplets and liver disease: from basic biology to clinical implications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 343-355.	8.2	427
167	Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. <i>Scientific Reports</i> , 2017, 7, 46458.	1.6	9
168	Liver Transplantation: the Role of Metabolic Syndrome. <i>Current Treatment Options in Gastroenterology</i> , 2017, 15, 316-331.	0.3	7

#	ARTICLE	IF	CITATIONS
169	Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. <i>Aids</i> , 2017, 31, 1621-1632.	1.0	166
170	Nonalcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey. <i>Liver International</i> , 2017, 37, 1706-1714.	1.9	28
171	Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease. <i>Clínica e Investigaci3n En Arteriosclerosis (English Edition)</i> , 2017, 29, 141-148.	0.1	4
172	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1084-1103.	1.8	311
173	Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. <i>Medicine (United States)</i> , 2017, 96, e6585.	0.4	21
174	Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1461-1468.	2.4	37
175	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017, 25, 1054-1062.e5.	7.2	748
176	Lessons from Epidemiology: The Burden of Liver Disease. <i>Digestive Diseases</i> , 2017, 35, 304-309.	0.8	104
177	Fibronectin Type III Domain-Containing Protein 5 rs3480 A≫G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669.	1.8	42
178	Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. <i>International Journal of Obesity</i> , 2017, 41, 1207-1213.	1.6	40
179	PPARs and nonalcoholic fatty liver disease. <i>Biochimie</i> , 2017, 136, 65-74.	1.3	210
180	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	1.8	110
181	Nonalcoholic Fatty Liver Disease in Children. <i>Pediatric Clinics of North America</i> , 2017, 64, 659-675.	0.9	35
182	Role of the <i>N</i>-acetylation polymorphism in solithromycin metabolism. <i>Pharmacogenomics</i> , 2017, 18, 765-772.	0.6	5
183	Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2017, 40, 388-394.	0.0	2
184	New trends on obesity and NAFLD in Asia. <i>Journal of Hepatology</i> , 2017, 67, 862-873.	1.8	759
185	NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 319-334.	0.9	649
186	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1277-1286.	0.2	38

#	ARTICLE	IF	CITATIONS
187	EASLâ€“EASDâ€“EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?. <i>Diabetologia</i> , 2017, 60, 1218-1222.	2.9	95
188	Ischaemic stroke and liver fibrosis. <i>Atherosclerosis</i> , 2017, 260, 153-155.	0.4	3
189	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1479.	2.4	2
190	Potential Regulators Driving the Transition in Nonalcoholic Fatty Liver Disease: a Stage-Based View. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 239-251.	1.1	16
191	Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Advances in Nutrition</i> , 2017, 8, 253-265.	2.9	38
192	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. <i>Gut</i> , 2017, 66, 1138-1153.	6.1	807
193	Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, G300-G313.	1.6	73
194	Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2017, 65, 1543-1556.	3.6	110
195	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 510-518.	1.9	169
196	Collaboration, Not Competition: The Role of Magnetic Resonance, Transient Elastography, and Liver Biopsy in the Diagnosis of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2017, 152, 479-481.	0.6	14
197	Non-alcoholic Fatty Liver Disease. In <i>Clinical Practice</i> , 2017, , 111-129.	0.1	1
198	Overview of Clinical Treatment Trials for NASH. <i>Current Hepatology Reports</i> , 2017, 16, 366-373.	0.4	0
199	Back to Byzance: Querelles byzantines over NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 1134-1136.	1.8	16
200	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. <i>American Journal of Gastroenterology</i> , 2017, 112, 1812-1823.	0.2	67
201	Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. <i>Translational Research</i> , 2017, 190, 25-39.e21.	2.2	91
202	Use of Liver Imaging and Biopsy in Clinical Practice. <i>New England Journal of Medicine</i> , 2017, 377, 756-768.	13.9	280
203	Epigenetics in Liver Fibrosis. <i>Seminars in Liver Disease</i> , 2017, 37, 219-230.	1.8	19
205	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , 2017, 1, 928-945.	2.0	11

#	ARTICLE	IF	CITATIONS
206	IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD – a pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1427-1434.	0.6	36
207	Hyperuricemia is not associated with severity of liver fibrosis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 694-697.	0.8	12
208	The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 629-634.	0.7	22
209	Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. <i>BMJ Open Gastroenterology</i> , 2017, 4, e000139.	1.1	95
210	Fragmento sÃ©rico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohÃ³lica en poblaciÃ³n chilena. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2017, 40, 388-394.	0.2	6
211	Review article: new treatments in nonâ€alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 494-507.	1.9	50
212	Putting it all together: Noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in adults and children. <i>Clinical Liver Disease</i> , 2017, 9, 134-137.	1.0	8
213	Serial combination of nonâ€invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <scp>NAFLD</scp>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627.	1.9	134
214	Model for endâ€stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 429-438.	2.0	9
215	Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. <i>Hepatology Communications</i> , 2017, 1, 421-428.	2.0	101
216	Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation. <i>Hepatology Communications</i> , 2017, 1, 370-378.	2.0	45
217	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. <i>Journal of Hepatology</i> , 2017, 67, 1265-1273.	1.8	730
218	Nonalcoholic fatty liver disease associated with metabolic syndrome: Influence of liver fibrosis stages on characteristics of very low-density lipoproteins. <i>Clinica Chimica Acta</i> , 2017, 473, 1-8.	0.5	23
219	Managing HCC in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 374-381.	0.4	1
220	Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2017, 377, 2063-2072.	13.9	864
221	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 903-913.	1.0	23
222	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. <i>BMJ Open</i> , 2017, 7, e015659.	0.8	50
223	Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients. <i>Aids</i> , 2017, 31, 1955-1964.	1.0	42

#	ARTICLE	IF	CITATIONS
224	Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. <i>Gastroenterology</i> , 2017, 153, 1006-1017.e5.	0.6	123
225	Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?. <i>Current Hepatology Reports</i> , 2017, 16, 152-157.	0.4	45
226	Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. <i>European Journal of Cancer</i> , 2017, 82, 103-114.	1.3	28
227	Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF- β 2. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	110
228	Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. <i>Journal of Translational Medicine</i> , 2017, 15, 106.	1.8	30
229	Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 332-344.	1.9	52
230	Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. <i>Liver International</i> , 2017, 37, 1065-1073.	1.9	145
231	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	0.6	32
232	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 159-165.	0.6	60
233	Enfermedad del h�gado graso no alcoh�lico, asociaci�n con la enfermedad cardiovascular y tratamiento (1). Enfermedad del h�gado graso no alcoh�lico y su asociaci�n con la enfermedad cardiovascular. <i>Cl�nica E Investigaci�n En Arteriosclerosis</i> , 2017, 29, 141-148.	0.4	9
234	Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. <i>Cell Biology and Toxicology</i> , 2017, 33, 5-14.	2.4	11
235	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751.	0.2	524
236	Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges. <i>Hepatology</i> , 2017, 65, 1058-1061.	3.6	20
237	Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 610-618.	1.8	195
238	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155.	3.6	177
239	Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 1018-1027.	0.7	7
240	Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. <i>International Journal of Biological Markers</i> , 2017, 32, 397-402.	0.7	27
242	Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance. <i>GE Portuguese Journal of Gastroenterology</i> , 2017, 24, 157-160.	0.3	2

#	ARTICLE	IF	CITATIONS
243	Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD. <i>Current Hepatology Reports</i> , 2017, 16, 298-307.	0.4	9
244	Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. <i>Journal of Clinical Investigation</i> , 2017, 127, 2697-2704.	3.9	137
245	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPAR1 α -regulated dermatopontin. <i>JCI Insight</i> , 2017, 2, .	2.3	96
247	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , 2017, 8, e3135-e3135.	2.7	34
248	Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-7.	0.7	10
249	Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , 2017, 23, 6571-6592.	1.4	138
250	Non-alcoholic fatty liver disease and cardiovascular risk. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2017, 8, 51.	0.5	101
251	Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. <i>Clinical Epidemiology</i> , 2017, Volume 9, 679-688.	1.5	37
252	Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2017, 12, e0188321.	1.1	48
253	Natural History of NAFLD/NASH. <i>Current Hepatology Reports</i> , 2017, 16, 391-397.	0.4	102
254	Free testosterone concentration is inversely associated with markers of liver fibrosis in men with type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2017, 64, 1137-1142.	0.7	13
255	Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. <i>Nutrients</i> , 2017, 9, 1077.	1.7	12
257	Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System. <i>Gastroenterology Research</i> , 2017, 10, 271-279.	0.4	30
258	New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation. <i>Annals of Hepatology</i> , 2017, 16, 932-940.	0.6	20
259	Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 135-137.	0.7	7
260	Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 274-282.	8.2	124
261	Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. <i>Radiology</i> , 2018, 286, 738-763.	3.6	215
262	Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. <i>Medical Hypotheses</i> , 2018, 113, 91-97.	0.8	34

#	ARTICLE	IF	CITATIONS
263	Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. <i>Oncogene</i> , 2018, 37, 3216-3228.	2.6	60
264	New insights into NAFLD and subclinical coronary atherosclerosis. <i>Journal of Hepatology</i> , 2018, 68, 890-892.	1.8	16
265	Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. <i>International Journal of Obesity</i> , 2018, 42, 1900-1911.	1.6	22
266	Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?. <i>Seminars in Liver Disease</i> , 2018, 38, 014-020.	1.8	21
267	Nonalcoholic Fatty Liver Disease in Children. <i>Seminars in Liver Disease</i> , 2018, 38, 001-013.	1.8	108
268	Nonalcoholic Fatty Liver Disease and Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1043-1045.	2.4	12
269	Association of Liver Fibrosis With Cardiovascular Diseases in the General Population. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007241.	1.3	67
270	The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. <i>Biomarkers in Medicine</i> , 2018, 12, 265-273.	0.6	14
271	Editorial: the impact of steatosis on liver stiffness quantification is minimal. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1416-1417.	1.9	1
272	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). <i>Hormones</i> , 2018, 17, 219-229.	0.9	37
273	Obesity and Nonalcoholic Fatty Liver Disease. , 2018, , 89-97.		3
274	Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). <i>BMJ Open Gastroenterology</i> , 2018, 5, e000198.	1.1	25
275	Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. <i>Liver International</i> , 2018, 38, 1793-1802.	1.9	79
276	Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. <i>Liver International</i> , 2018, 38, 2060-2068.	1.9	72
277	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
278	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. <i>Liver International</i> , 2018, 38, 2082-2090.	1.9	47
279	Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1946-1951.	1.1	2
280	Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) $\alpha/\beta/\delta$ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2246-2265.	2.9	87

#	ARTICLE	IF	CITATIONS
281	Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs, 2018, 27, 301-311.	1.9	95
282	Is a fatty liver (always or ever) bad for the heart?. European Heart Journal, 2018, 39, 394-396.	1.0	4
283	Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. Hepatology International, 2018, 12, 44-55.	1.9	27
284	Steatosis affects the sensitivity but not the specificity of non-invasive fibrosis tests in non-alcoholic fatty liver disease – implications for screening strategies. Liver International, 2018, 38, 224-226.	1.9	5
285	Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver International, 2018, 38, 1849-1859.	1.9	72
286	Nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 637-644.	0.8	8
287	Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1974-1982.e7.	2.4	46
288	SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. Scientific Reports, 2018, 8, 725.	1.6	23
289	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatology Communications, 2018, 2, 48-57.	2.0	200
290	Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 58-68.	2.0	42
291	Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatology Communications, 2018, 2, 199-210.	2.0	102
292	Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver International, 2018, 38, 64-66.	1.9	57
293	Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men. Clinical Gastroenterology and Hepatology, 2018, 16, 1131-1137.e5.	2.4	42
294	The Natural History of Nonalcoholic Fatty Liver Disease – An Evolving View. Clinics in Liver Disease, 2018, 22, 11-21.	1.0	189
295	Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 631-644.	1.9	77
296	MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. European Journal of Radiology, 2018, 98, 82-89.	1.2	46
297	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 282-294.	2.9	36
298	Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. The Lancet Gastroenterology and Hepatology, 2018, 3, 66-72.	3.7	28

#	ARTICLE	IF	CITATIONS
299	Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. <i>Hepatology International</i> , 2018, 12, 26-36.	1.9	41
300	Predicting Fibrosis Progression in Renal Transplant Recipients Using Laser-Based Infrared Spectroscopic Imaging. <i>Scientific Reports</i> , 2018, 8, 686.	1.6	13
302	Liver fat imaging—a clinical overview of ultrasound, CT, and MR imaging. <i>British Journal of Radiology</i> , 2018, 91, 20170959.	1.0	164
303	Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2018, 155, 307-310.e2.	0.6	113
304	Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 87-91.	1.0	12
305	Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Clinical Liver Disease</i> , 2018, 11, 98-104.	1.0	51
306	Lean NAFLD: A not so benign condition?. <i>Hepatology Communications</i> , 2018, 2, 5-8.	2.0	48
307	Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). <i>Medicine (United States)</i> , 2018, 97, e0214.	0.4	143
308	Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1511-1520.e5.	2.4	111
309	The hedgehog pathway in nonalcoholic fatty liver disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2018, 53, 264-278.	2.3	37
310	Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 444-451.	1.1	11
311	Serum folic acid levels are associated with the presence and severity of liver steatosis in Chinese adults. <i>Clinical Nutrition</i> , 2018, 37, 1752-1758.	2.3	30
312	A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. <i>Liver International</i> , 2018, 38, 155-163.	1.9	5
313	Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 70-85.	1.4	358
314	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1684.	2.4	0
315	The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 86-98.	1.4	117
316	Hepatic iron is the major determinant of serum ferritin in NAFLD patients. <i>Liver International</i> , 2018, 38, 164-173.	1.9	65
317	Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. <i>Internal Medicine Journal</i> , 2018, 48, 144-151.	0.5	80

#	ARTICLE	IF	CITATIONS
318	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 1-10.	1.0	85
319	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. <i>Journal of Hepatology</i> , 2018, 68, 147-156.	1.8	72
320	Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 735-742.	1.1	11
321	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767.	3.6	528
322	Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 11-20.	8.2	3,487
323	The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. <i>Hepatology</i> , 2018, 67, 549-559.	3.6	435
324	Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. <i>Diabetic Medicine</i> , 2018, 35, 89-98.	1.2	35
325	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. <i>Journal of Gastroenterology</i> , 2018, 53, 181-196.	2.3	61
326	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 607-617.	1.8	41
329	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 351-367.	1.4	47
330	The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2018, 22, 109-119.	1.0	46
331	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. <i>Journal of Hepatology</i> , 2018, 68, 305-315.	1.8	427
332	Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions. <i>Journal of Hepatology</i> , 2018, 68, 296-304.	1.8	92
333	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. <i>Journal of Hepatology</i> , 2018, 68, 335-352.	1.8	495
334	Pharmacotherapy for NASH: Current and emerging. <i>Journal of Hepatology</i> , 2018, 68, 362-375.	1.8	249
335	Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 268-278.	1.9	33
336	A practical clinical approach to liver fibrosis. <i>Singapore Medical Journal</i> , 2018, 59, 628-633.	0.3	14
337	Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 143-146.	0.7	5

#	ARTICLE	IF	CITATIONS
338	Beyond the liver in patients with non-alcoholic fatty liver disease (NAFLD)â€”cause for concern?. <i>Hepatobiliary Surgery and Nutrition</i> , 2018, 7, 138-142.	0.7	1
339	Lipometabolism and Glycometabolism in Liver Diseases. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	46
340	Nonalcoholic fatty liver disease with prolactin-secreting pituitary adenoma in an adolescent. <i>Medicine (United States)</i> , 2018, 97, e12879.	0.4	4
341	Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2018, , .	1.5	3
342	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121.	1.7	41
343	Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease. <i>Scientific Reports</i> , 2018, 8, 16559.	1.6	17
344	Nonâ€”alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects. <i>Pediatric Diabetes</i> , 2018, 20, 41-47.	1.2	6
345	Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	151
346	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. <i>Contemporary Clinical Trials</i> , 2018, 75, 67-71.	0.8	16
347	Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. <i>BMC Gastroenterology</i> , 2018, 18, 165.	0.8	27
348	Non-alcoholic fatty liver disease and cardiovascular risk: an update. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1175-1177.	1.4	10
349	Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlrâ€”Leiden Mice. <i>Hepatology Communications</i> , 2018, 2, 1513-1532.	2.0	49
350	Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease. <i>Przegląd Gastroenterologiczny</i> , 2018, 13, 337-339.	0.3	0
351	Editorial: stepwise risk stratification for both F3 and F4 fibrosis stage in NAFLD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1317-1318.	1.9	1
352	Editorial: FibroTest to predict liverâ€”related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1319-1320.	1.9	1
353	Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 315-320.	1.2	11
354	Obesity and nonalcoholic fatty liver disease: current perspectives. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2018, Volume 11, 533-542.	1.1	167
355	Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging. <i>Annals of Diagnostic Pathology</i> , 2018, 37, 83-90.	0.6	33

#	ARTICLE	IF	CITATIONS
356	Nonalcoholic Liver Disease in Children and Adolescents. <i>Clinics in Liver Disease</i> , 2018, 22, 723-733.	1.0	21
357	Non-alcoholic fatty liver disease—a chronic disease of the 21 st century. <i>Journal of Biomedical Research</i> , 2018, 32, 327-335.	0.7	15
358	Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2018, 24, 2073-2082.	1.4	19
359	Magnetic Resonance Elastography of Liver. <i>Topics in Magnetic Resonance Imaging</i> , 2018, 27, 319-333.	0.7	92
360	Metalloproteinases in non-alcoholic fatty liver disease and their behavior in liver fibrosis. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2018, 41, .	0.3	5
361	The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. <i>United European Gastroenterology Journal</i> , 2018, 6, 1372-1379.	1.6	5
362	An exploratory study examining how nano-liquid chromatography–mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 170.	2.3	8
363	Inhibiting Inflammasomes with Small Molecules. <i>Experientia Supplementum (2012)</i> , 2018, 108, 343-400.	0.5	2
364	Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. <i>Annals of Gastroenterology</i> , 2018, 31, 288-295.	0.4	54
365	Nutritional issues in patients with obesity and cirrhosis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3330-3346.	1.4	59
366	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
367	A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care. <i>Hepatology Communications</i> , 2018, 2, 897-909.	2.0	54
368	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153.	0.6	253
369	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. <i>PLoS ONE</i> , 2018, 13, e0202226.	1.1	12
370	NAFLD and cardiovascular disease. <i>Porto Biomedical Journal</i> , 2018, 3, e2.	0.4	7
371	Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 461-478.	8.2	400
372	Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. <i>Journal of Hepatology</i> , 2018, 69, 718-735.	1.8	474
373	Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?. <i>Journal of Hepatology</i> , 2018, 69, 755-756.	1.8	1

#	ARTICLE	IF	CITATIONS
374	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterology & Hepatology</i> (English Edition), 2018, 41, 328-349.	0.0	7
375	Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. <i>Digestive and Liver Disease</i> , 2018, 50, 1062-1067.	0.4	9
376	The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. <i>Clinical and Experimental Hepatology</i> , 2018, 4, 1-6.	0.6	51
377	Mechanisms of NAFLD development and therapeutic strategies. <i>Nature Medicine</i> , 2018, 24, 908-922.	15.2	2,392
378	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. <i>Gastroenterology</i> , 2018, 155, 443-457.e17.	0.6	536
379	The association of non-alcoholic fatty liver disease and atrial fibrillation: a review. <i>Annals of Medicine</i> , 2018, 50, 371-380.	1.5	20
380	Speculation of the Time-Dependent Change of FIB4 Index in Patients with Nonalcoholic Fatty Liver Disease: A Retrospective Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	5
381	Enhanced Liver Fibrosis Score as a Predictor of Hepatocellular Carcinoma. <i>Clinical Chemistry</i> , 2018, 64, 1404-1405.	1.5	7
382	Current Prevention and Treatment Options for NAFLD. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 149-157.	0.8	15
383	Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	16
384	Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E795-E814.	1.8	9
385	Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis. <i>American Journal of Medicine</i> , 2018, 131, 1515.e1-1515.e10.	0.6	26
386	The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2223-2232.	0.7	103
387	CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G483-G493.	1.6	46
388	Key Inflammatory Processes in Human NASH Are Reflected in <i>Ldlr</i> ^{-/-} Leiden Mice: A Translational Gene Profiling Study. <i>Frontiers in Physiology</i> , 2018, 9, 132.	1.3	35
389	Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis. <i>Digestive Diseases</i> , 2018, 36, 427-436.	0.8	43
390	Nonalcoholic steatohepatitis in posttransplantation liver: Review article. <i>Revista Da Associação Médica Brasileira</i> , 2018, 64, 187-194.	0.3	11
391	Urea cycle dysregulation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2018, 69, 905-915.	1.8	123

#	ARTICLE	IF	CITATIONS
392	Saccharin Increases Fasting Blood Glucose but Not Liver Insulin Resistance in Comparison to a High Fructose-Fed Rat Model. <i>Nutrients</i> , 2018, 10, 341.	1.7	12
393	Fatty Liver Disease. , 2018, , 308-371.		14
394	Patients with stage 3 compared to stage 4 liver fibrosis have lower frequency of and longer time to liver disease complications. <i>PLoS ONE</i> , 2018, 13, e0197117.	1.1	17
396	Imaging of nonalcoholic fatty liver disease and its clinical utility. <i>Hormones</i> , 2018, 17, 69-81.	0.9	37
397	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. <i>Paediatric Drugs</i> , 2018, 20, 315-329.	1.3	23
398	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018, 53, 1216-1224.	2.3	68
399	The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). <i>Non-coding RNA</i> , 2018, 4, 18.	1.3	42
400	Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2018, 16, 130.	2.3	177
401	An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis. <i>Scientific Reports</i> , 2018, 8, 12414.	1.6	53
402	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , 2018, 24, 3361-3373.	1.4	375
403	Burden of non-alcoholic fatty liver disease in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1-11.	1.4	39
404	Non-alcoholic fatty liver disease. <i>Clinical Medicine</i> , 2018, 18, 245-250.	0.8	171
405	Fatty Liver and the Forensic Pathologist. <i>Academic Forensic Pathology</i> , 2018, 8, 296-310.	0.3	10
407	Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0192396.	1.1	18
408	NAFLD/NASH. <i>Acta Hepatologica Japonica</i> , 2018, 59, 83-91.	0.0	1
409	Non-alcoholic fatty liver disease and the interface between primary and secondary care. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 509-517.	3.7	106
410	Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. <i>Hepatology Communications</i> , 2018, 2, 778-785.	2.0	28
411	Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). <i>Diabetes Care</i> , 2018, 41, 1801-1808.	4.3	403

#	ARTICLE	IF	CITATIONS
412	Repeating measurements by transient elastography in nonalcoholic fatty liver disease patients with high liver stiffness. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 241-248.	1.4	28
413	Cardiometabolic effects of antidiabetic drugs in nonalcoholic fatty liver disease. <i>Clinical Physiology and Functional Imaging</i> , 2019, 39, 122-127.	0.5	4
414	Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 630-637.e8.	2.4	254
415	Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese nonalcoholic fatty liver disease patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 207-214.	1.4	30
416	Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Hepatology</i> , 2019, 69, 64-75.	3.6	107
417	ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis. <i>Hepatology</i> , 2019, 69, 1075-1086.	3.6	174
418	Nonalcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. <i>Liver International</i> , 2019, 39, 2094-2101.	1.9	43
419	Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). <i>Cells</i> , 2019, 8, 845.	1.8	92
420	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with nonalcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2317-2329.	1.9	24
421	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 67-80.	1.5	52
422	Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. <i>Scientific Reports</i> , 2019, 9, 11124.	1.6	94
423	Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis. <i>PLoS ONE</i> , 2019, 14, e0220612.	1.1	17
424	Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 849-866.	1.4	32
425	Wogonin attenuates liver fibrosis via regulating hepatic stellate cell activation and apoptosis. <i>International Immunopharmacology</i> , 2019, 75, 105671.	1.7	37
426	Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. <i>Medicina Clínica</i> , 2019, 153, 169-177.	0.3	18
427	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2019, 19, 122.	0.8	81
428	AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p. <i>PLoS ONE</i> , 2019, 14, e0219764.	1.1	29
429	Liver organoids: from basic research to therapeutic applications. <i>Gut</i> , 2019, 68, 2228-2237.	6.1	222

#	ARTICLE	IF	CITATIONS
430	Who Should Treat Fatty Liver Disease: Primary Care or Hepatology?. <i>Clinical Liver Disease</i> , 2019, 13, 158-161.	1.0	0
431	Lipoprotein Lipase Upregulation in Hepatic Stellate Cells Exacerbates Liver Fibrosis in Nonalcoholic Steatohepatitis in Mice. <i>Hepatology Communications</i> , 2019, 3, 1098-1112.	2.0	39
432	Nonalcoholic fatty liver disease with advanced fibrosis as a multi-systemic disease: proceed with caution. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 170-172.	0.7	2
433	Referral pathways for patients with NAFLD based on noninvasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> , 2019, 39, 2052-2060.	1.9	49
434	Reversal of NASH fibrosis with pharmacotherapy. <i>Hepatology International</i> , 2019, 13, 534-545.	1.9	13
435	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 193-203.	1.9	112
436	Association Between Nonalcoholic Fatty Liver Disease and Future Deterioration of Metabolic Health: A Cohort Study. <i>Obesity</i> , 2019, 27, 1360-1366.	1.5	15
437	Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease. <i>JAMA Internal Medicine</i> , 2019, 179, 1262.	2.6	159
438	Biphasic Effect of Sildenafil on Energy Sensing is Mediated by Phosphodiesterases 2 and 3 in Adipocytes and Hepatocytes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2992.	1.8	7
439	Treatment of Fatty Liver Disease—Time to Implement Common Sense Measures. <i>JAMA Internal Medicine</i> , 2019, 179, 1272.	2.6	1
440	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
441	NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 891-902.	3.1	80
442	Interleukin-32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance. <i>Hepatology Communications</i> , 2019, 3, 1205-1220.	2.0	38
444	Individualized risk prediction of significant fibrosis in nonalcoholic fatty liver disease using a novel nomogram. <i>United European Gastroenterology Journal</i> , 2019, 7, 1124-1134.	1.6	29
445	Effect of alcohol consumption on nonalcoholic fatty liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 70-70.	1.5	16
446	Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 2772-2778.	1.3	37
447	A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice. <i>Hepatology Communications</i> , 2019, 3, 1221-1234.	2.0	36
448	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1113-1123.	1.6	55

#	ARTICLE	IF	CITATIONS
449	Hepatocellular carcinoma and non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2019, 13, 688-694.	1.9	56
450	Non-alcoholic fatty liver disease (NAFLD) "Treat to target, but the goalposts are in the wrong place. <i>GastroHep</i> , 2019, 1, 203-204.	0.3	0
451	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. <i>Hepatology Communications</i> , 2019, 3, 1472-1481.	2.0	26
452	Non-alcoholic fatty liver disease. <i>Medicine</i> , 2019, 47, 728-733.	0.2	5
453	Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. <i>BMC Genomics</i> , 2019, 20, 862.	1.2	42
454	NAFLD Histology: a Critical Review and Comparison of Scoring Systems. <i>Current Hepatology Reports</i> , 2019, 18, 473-481.	0.4	8
455	Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 522-524.	0.7	3
456	Should We Screen High-Risk Populations for NAFLD?. <i>Current Hepatology Reports</i> , 2019, 18, 433-443.	0.4	6
457	Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. <i>Hepatology Communications</i> , 2019, 3, 1322-1333.	2.0	61
458	Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. <i>Hepatology Communications</i> , 2019, 3, 1459-1471.	2.0	150
459	Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116524.	0.3	28
460	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. <i>Lancet HIV</i> , 2019, 6, e821-e830.	2.1	50
461	Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1100-1111.	1.9	27
462	Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3104.	1.2	135
463	Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 53-53.	1.5	34
464	The miR-FIB-Score: A Serological miRNA-Based Scoring Algorithm for the Diagnosis of Significant Liver Fibrosis. <i>Cells</i> , 2019, 8, 1003.	1.8	19
465	Association between nonalcoholic fatty liver disease and cardiac function and structure "a meta-analysis. <i>Endocrine</i> , 2019, 66, 467-476.	1.1	27
466	Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-14.	3.2	139

#	ARTICLE	IF	CITATIONS
467	Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis Literature Review. <i>Frontiers in Medicine</i> , 2019, 6, 202.	1.2	97
468	New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease. <i>Cells</i> , 2019, 8, 1062.	1.8	17
469	Signal transducer and activator of transcriptions (STATs) at the crossroads of obesity-linked non-alcoholic steatohepatitis and hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 407-410.	0.7	1
470	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 169-177.	0.1	7
471	NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 3415.	1.2	90
472	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e627.	0.6	0
473	Efficacy of diacerein in reducing liver steatosis and fibrosis in patients with type 2 diabetes and non-alcoholic fatty liver disease: A randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1266-1270.	2.2	25
474	Race/ethnicity-based temporal changes in prevalence of NAFLD-related advanced fibrosis in the United States, 2005-2016. <i>Hepatology International</i> , 2019, 13, 205-213.	1.9	63
475	Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. <i>Atherosclerosis</i> , 2019, 282, 110-120.	0.4	68
476	Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1633-1640.	1.4	20
477	Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis Effects of a peroxisome proliferator-activated receptor gamma (PPAR- γ) agonist and a glucagon-like peptide-1 analogue. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 926-933.	2.5	14
478	Consenso mexicano de la enfermedad por hÃgado graso no alcohÃlico. <i>Revista De GastroenterologÃa De MÃxico</i> , 2019, 84, 69-99.	0.4	26
479	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. <i>Liver International</i> , 2019, 39, 758-769.	1.9	75
480	Transient Elastography and Controlled Attenuation Parameter (CAP) in the Assessment of Liver Steatosis in Severe Adult Growth Hormone Deficiency. <i>Frontiers in Endocrinology</i> , 2019, 10, 364.	1.5	7
481	Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1884-1894.	1.9	31
482	Combined obeticholic acid and elafibanor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. <i>Scientific Reports</i> , 2019, 9, 9046.	1.6	35
483	Retained NK Cell Phenotype and Functionality in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1255.	2.2	58
484	Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. <i>Digestive and Liver Disease</i> , 2019, 51, 1214-1222.	0.4	52

#	ARTICLE	IF	CITATIONS
485	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidaseâ€4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , 2019, 49, 1147-1161.	1.8	9
486	Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2776-2784.e4.	2.4	108
487	Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. <i>Current Obesity Reports</i> , 2019, 8, 243-254.	3.5	37
488	Nonâ€alcoholic fatty liver disease, liver fibrosis score and cognitive function in middleâ€aged adults: The Framingham Study. <i>Liver International</i> , 2019, 39, 1713-1721.	1.9	68
489	Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm. <i>Liver International</i> , 2019, 39, 1722-1731.	1.9	21
490	Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism. <i>JHEP Reports</i> , 2019, 1, 30-43.	2.6	176
491	Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2215.	1.8	42
492	Nonâ€alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver â€ a human galactose positron emission tomography study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 84-92.	1.9	7
493	Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. <i>BMC Medicine</i> , 2019, 17, 95.	2.3	192
494	Diagnosis and management of non-alcoholic fatty liver disease. <i>Postgraduate Medical Journal</i> , 2019, 95, 314-322.	0.9	70
495	Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. <i>Digestive and Liver Disease</i> , 2019, 51, 1400-1408.	0.4	31
497	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1948.	1.8	127
498	Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 9037-9047.	1.6	40
499	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. <i>Frontline Gastroenterology</i> , 2019, 10, 337-346.	0.9	48
500	Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment. <i>Hepatology Communications</i> , 2019, 3, 605-613.	2.0	14
501	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855.	3.6	64
502	Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. <i>Liver International</i> , 2019, 39, 1535-1544.	1.9	23
503	The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke. <i>Frontiers in Neurology</i> , 2019, 10, 375.	1.1	9

#	ARTICLE	IF	CITATIONS
504	Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1745.	1.8	39
505	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927.	3.6	226
506	From NASH to HCC: current concepts and future challenges. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 411-428.	8.2	872
507	Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1214-1222.	1.9	55
508	Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1867-1876.e3.	2.4	31
509	Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1077-1085.	1.9	35
510	Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 542-550.	0.7	27
511	Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 328-334.	0.6	55
512	Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue. <i>Liver International</i> , 2019, 39, 1217-1225.	1.9	11
513	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1325-1334.	1.9	48
514	Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography. <i>Hepatology</i> , 2019, 70, 127-141.	3.6	21
515	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. <i>Experimental Biology and Medicine</i> , 2019, 244, 408-418.	1.1	19
516	Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 776-791.	2.0	50
517	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 371-378.	1.8	301
518	Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. <i>Liver International</i> , 2019, 39, 1343-1354.	1.9	18
519	Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1761-1770.	1.1	19
520	The Mexican consensus on nonalcoholic fatty liver disease. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2019, 84, 69-99.	0.1	6
521	Human relaxin-2 attenuates hepatic steatosis and fibrosis in mice with non-alcoholic fatty liver disease. <i>Laboratory Investigation</i> , 2019, 99, 1203-1216.	1.7	22

#	ARTICLE	IF	CITATIONS
522	From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. <i>Proceedings of the Nutrition Society</i> , 2019, 78, 290-304.	0.4	36
523	Novel Serum Biomarkers for Noninvasive Diagnosis and Screening of Nonalcoholic Fatty Liver Disease-Related Hepatic Fibrosis. <i>OMICS A Journal of Integrative Biology</i> , 2019, 23, 181-189.	1.0	21
524	Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). <i>Abdominal Radiology</i> , 2019, 44, 1816-1824.	1.0	17
525	Transcriptional regulation of Hepatic Stellate Cell activation in NASH. <i>Scientific Reports</i> , 2019, 9, 2324.	1.6	65
526	Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 361-374.	1.4	88
527	Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. <i>Diabetes and Metabolism Journal</i> , 2019, 43, 31.	1.8	109
528	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1148-1156.e4.	2.4	71
529	Nonalcoholic Fatty Liver Disease and the Heart. <i>Journal of the American College of Cardiology</i> , 2019, 73, 948-963.	1.2	259
530	Body mass index in early pregnancy and future risk of severe liver disease: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 789-796.	1.9	5
531	The degree of hepatic steatosis associates with impaired cardiac and autonomic function. <i>Journal of Hepatology</i> , 2019, 70, 1203-1213.	1.8	45
532	Use of Steatotic Grafts in Liver Transplantation: Current Status. <i>Liver Transplantation</i> , 2019, 25, 771-786.	1.3	22
533	Serum ferritin as a biomarker for NAFLD: ready for prime time?. <i>Hepatology International</i> , 2019, 13, 110-112.	1.9	14
534	Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. <i>BMJ Open</i> , 2019, 9, e023597.	0.8	38
536	Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 551-560.	0.7	29
537	Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , 2019, 19, 27.	0.8	15
538	A Novel Discovery: Holistic Efficacy at the Special Organ Level of Pungent Flavored Compounds from Pungent Traditional Chinese Medicine. <i>International Journal of Molecular Sciences</i> , 2019, 20, 752.	1.8	10
539	Relationship between <i>Streptococcus mutans</i> expressing Cnm in the oral cavity and non-alcoholic steatohepatitis: a pilot study. <i>BMJ Open Gastroenterology</i> , 2019, 6, e000329.	1.1	5
541	Medical Management after Liver Transplantation. <i>Digestive Disease Interventions</i> , 2019, 03, 305-313.	0.3	0

#	ARTICLE	IF	CITATIONS
542	Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the Kuopio Ischaemic Heart Disease Risk Factor Study Cohort. <i>BMJ Open</i> , 2019, 9, e031420.	0.8	10
543	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. <i>Future Medicinal Chemistry</i> , 2019, 11, 2171-2192.	1.1	30
544	Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. <i>Scientific Reports</i> , 2019, 9, 16810.	1.6	34
545	Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model. <i>Nutrients</i> , 2019, 11, 2834.	1.7	16
546	The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5613.	1.8	39
547	Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2019, 9, 19601.	1.6	18
548	The ZJU index is a powerful surrogate marker for NAFLD in severely obese North American women. <i>PLoS ONE</i> , 2019, 14, e0224942.	1.1	16
549	Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. <i>Nutrients</i> , 2019, 11, 2871.	1.7	14
550	Liver Disease Among Renal Transplant Recipients. , 2019, , 539-565.		0
551	Long Noncoding RNA Inc-HC Regulates PPAR β -Mediated Hepatic Lipid Metabolism through miR-130b-3p. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 954-965.	2.3	40
552	The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. , 0, , .		9
553	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 444-454.	0.4	1
554	The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2019, 29, 509-512.	0.4	6
555	Studies on non-alcoholic fatty liver disease should stratify by disease severity. <i>BMJ: British Medical Journal</i> , 2019, 367, l6495.	2.4	4
556	Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00066.	1.3	19
557	Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 620-629.	0.2	52
558	Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis. <i>Medicine (United States)</i> , 2019, 98, e14896.	0.4	10
559	Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 224-229.	0.8	6

#	ARTICLE	IF	CITATIONS
560	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, e86-e94.	0.9	53
561	Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2019, 80, 474-480.	0.9	18
562	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. <i>American Journal of Gastroenterology</i> , 2019, 114, 579-590.	0.2	27
563	Obesity Is the Most Common Risk Factor for Chronic Liver Disease: Results From a Risk Stratification Pathway Using Transient Elastography. <i>American Journal of Gastroenterology</i> , 2019, 114, 1744-1752.	0.2	32
564	Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 142-146.	1.1	17
565	The significance of paired biopsies in estimating disease progression in patients with nonalcoholic steatohepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 897-898.	0.8	0
566	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2019, 114, 916-928.	0.2	57
567	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 313-324.	5.5	566
568	Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. <i>Obesity Surgery</i> , 2019, 29, 99-108.	1.1	24
569	Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 543-550.e2.	2.4	56
570	Prognostic molecular markers in pediatric liver disease – Are there any?. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 577-586.	1.8	4
571	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. <i>Transplantation</i> , 2019, 103, 22-27.	0.5	296
572	<sc>HOMA</sc>: An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1390-1395.	1.4	67
573	Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2019, 68, 1884-1892.	6.1	48
574	Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. <i>Gut</i> , 2019, 68, 1667-1675.	6.1	130
575	Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α -glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8534-8546.	1.2	34
576	Non-alcoholic fatty liver disease – A global public health perspective. <i>Journal of Hepatology</i> , 2019, 70, 531-544.	1.8	1,345
577	Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 69-82.	0.9	15

#	ARTICLE	IF	CITATIONS
578	Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 64-73.	1.9	77
579	Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. <i>Pharmacoeconomics</i> , 2019, 37, 267-278.	1.7	18
580	Animal Models When Examining the Gut-Liver Axis. , 2019, , 235-264.		0
581	Adult Non-alcoholic Fatty Liver Disease (NAFLD). , 2019, , 23-46.		0
582	Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?. <i>Obesity Reviews</i> , 2019, 20, 353-363.	3.1	42
583	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G462-G472.	1.6	162
584	An Inhibitor of Arginine-Glycine-Aspartate-Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. <i>Hepatology Communications</i> , 2019, 3, 246-261.	2.0	28
585	Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2019, 13, 424-428.	1.8	13
586	Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2019, 70, 735-744.	1.8	60
587	Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2019, 156, 88-95.e5.	0.6	73
588	Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1411-1416.	1.4	6
589	Reproductive Endocrinology of Nonalcoholic Fatty Liver Disease. <i>Endocrine Reviews</i> , 2019, 40, 417-446.	8.9	73
590	Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. <i>Journal of Hepatology</i> , 2019, 70, 133-141.	1.8	149
591	Cardiovascular risk factors in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 197-204.	1.9	75
592	Liver parameters as part of a non-invasive model for prediction of all-cause mortality after myocardial infarction. <i>Archives of Medical Science</i> , 2020, 16, 71-80.	0.4	10
593	The association between liver fat and systemic calcified atherosclerosis. <i>Journal of Vascular Surgery</i> , 2020, 71, 204-211.e4.	0.6	27
594	GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 135-141.	1.9	91
595	A review of the clinical utility of the Enhanced Liver Fibrosis test in multiple aetiologies of chronic liver disease. <i>Annals of Clinical Biochemistry</i> , 2020, 57, 36-43.	0.8	5

#	ARTICLE	IF	CITATIONS
596	Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 710-718.e4.	2.4	10
597	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. <i>Gut</i> , 2020, 69, 1116-1126.	6.1	27
598	NASH-inducing Diets in Göttingen Minipigs. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 211-221.	0.4	14
599	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
600	Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 849-860.	3.6	57
601	Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease. <i>Gastroenterology</i> , 2020, 158, 200-214.	0.6	121
602	Fatty Liver Disease: A Practical Approach. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 62-70.	1.2	15
603	Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 255-262.	0.4	43
604	Insulin resistance, but not insulin response, during oral glucose tolerance test (OGTT) is associated to worse histological outcome in obese NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 106-113.	1.1	19
605	Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 245-254.	0.4	24
606	Organokines in disease. <i>Advances in Clinical Chemistry</i> , 2020, 94, 261-321.	1.8	24
607	Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 874-892.	3.6	62
608	Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. <i>Nutrition and Cancer</i> , 2020, 72, 884-891.	0.9	9
609	Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 90-96.	1.4	7
610	Liver Disease, Nonalcoholic Fatty. , 2020, , 408-413.		1
611	Hypothetical treatment of patients with non-alcoholic steatohepatitis: Potential impact on important clinical outcomes. <i>Liver International</i> , 2020, 40, 308-318.	1.9	4
612	Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. <i>Diabetologia</i> , 2020, 63, 253-260.	2.9	95
613	qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2020, 71, 1953-1966.	3.6	66

#	ARTICLE	IF	CITATIONS
614	Metabolic syndrome, but not nonalcoholic fatty liver disease, increases 10-year mortality: A prospective, community-cohort study. <i>Liver International</i> , 2020, 40, 101-106.	1.9	15
615	Liver fibrosis by FibroScan [®] independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. <i>Liver International</i> , 2020, 40, 347-354.	1.9	59
616	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 5031-5073.	2.9	67
617	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 45-62.	1.0	5
618	Nutrition and Nonalcoholic Fatty Liver Disease. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 63-94.	1.0	44
619	Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma. <i>Pathology International</i> , 2020, 70, 140-154.	0.6	7
620	High rates of ineligibility for participation in trials of new therapies in non-alcoholic steatohepatitis: a systematic review. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1023-1029.	0.8	4
621	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	0.8	92
622	High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2081-2090.e9.	2.4	85
623	Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events: A Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2324-2331.e4.	2.4	136
624	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. <i>Journal of Hepatology</i> , 2020, 72, 816-827.	1.8	165
625	Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 106-113.	0.6	18
626	Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 420-425.	0.8	22
627	Comparison of 2D Shear Wave Elastography, Transient Elastography, and MR Elastography for the Diagnosis of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>American Journal of Roentgenology</i> , 2020, 214, W20-W26.	1.0	87
628	Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. <i>Hepatology</i> , 2020, 72, 430-440.	3.6	48
629	Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. <i>JGH Open</i> , 2020, 4, 433-440.	0.7	10
630	Epidemiological differences of common liver conditions between Asia and the West. <i>JGH Open</i> , 2020, 4, 332-339.	0.7	18
631	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2112-2119.	1.1	68

#	ARTICLE	IF	CITATIONS
632	The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 231-238.	0.8	13
633	Evolution of NAFLD and Its Management. <i>Nutrition in Clinical Practice</i> , 2020, 35, 72-84.	1.1	164
634	Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. <i>Endocrine</i> , 2020, 67, 569-578.	1.1	7
635	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	1.8	52
636	Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 581-589.	1.9	75
637	New drugs for NAFLD: lessons from basic models to the clinic. <i>Hepatology International</i> , 2020, 14, 8-23.	1.9	61
638	Predicting NASH response with liver fat: Are we back to square one?. <i>Journal of Hepatology</i> , 2020, 72, 386-388.	1.8	12
639	Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 748-753.	0.8	19
640	Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2020, 57, 613-618.	1.2	41
641	Liver Stiffness by Magnetic Resonance Elastography Predicts Future Cirrhosis, Decompensation, and Death in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1915-1924.e6.	2.4	57
642	Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis. <i>Hepatology Communications</i> , 2020, 4, 1578-1590.	2.0	71
643	Advanced Liver Fibrosis Predicts Unfavorable Long-Term Prognosis in First-Ever Ischemic Stroke or Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2020, 49, 474-480.	0.8	18
644	The Burden of NAFLD Worldwide. , 2020, , 15-24.		0
645	Correlation between the small dense LDL level and nonalcoholic fatty liver disease. <i>Medicine (United States)</i> 2020;99(14):e20200. doi:10.1097/MD.0000000000002020	0.4	9
646	NAFLD and cardiovascular diseases: a clinical review. <i>Clinical Research in Cardiology</i> , 2021, 110, 921-937.	1.5	285
647	Glutamine Breakdown as a Potential Metabolic Biomarker for Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 195-196.	2.3	1
648	Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1297-1305.	1.0	19
649	MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study. <i>Liver International</i> , 2020, 40, 2242-2251.	1.9	48

#	ARTICLE	IF	CITATIONS
650	The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00127.	1.0	15
651	Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00134.	1.0	11
652	Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. <i>Cells</i> , 2020, 9, 2458.	1.8	40
653	MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Gut</i> , 2021, 70, 1946-1953.	6.1	78
654	Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8761.	1.8	27
655	Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2202-2204.	2.4	7
656	Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China. <i>Medicine (United States)</i> , 2020, 99, e23360.	0.4	8
657	Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 2233-2239.	1.8	9
658	Two-Week Isocaloric Time-Restricted Feeding Decreases Liver Inflammation without Significant Weight Loss in Obese Mice with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9156.	1.8	11
659	Association of arterial stiffness with the histological severity of nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2020, 14, 1048-1056.	1.9	9
660	Complications of Non-Alcoholic Fatty Liver Disease in Extrahepatic Organs. <i>Diagnostics</i> , 2020, 10, 912.	1.3	15
661	Advances in ultrasound elastography for nonalcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2020, 47, 521-533.	0.6	17
662	Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 1025-1033.	1.4	11
663	Efficacy of Dietary Supplements to Reduce Liver Fat. <i>Nutrients</i> , 2020, 12, 2302.	1.7	6
664	Non-Alcoholic fatty liver disease increases the risk of incident chronic kidney disease. <i>United European Gastroenterology Journal</i> , 2020, 8, 942-948.	1.6	43
665	Screening strategies for nonalcoholic fatty liver disease in type 2 diabetes: Insights from NHANES 2005-2016. <i>Diabetes Research and Clinical Practice</i> , 2020, 167, 108358.	1.1	19
666	Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. <i>EClinicalMedicine</i> , 2020, 25, 100445.	3.2	15
667	Histologic parameter score does not predict short-term survival in severe alcoholic hepatitis. <i>United European Gastroenterology Journal</i> , 2020, 8, 1003-1012.	1.6	12

#	ARTICLE	IF	CITATIONS
670	Breaking Down Barriers to Physical Activity in Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3604-3611.	1.1	30
671	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. <i>Journal of Medical Ultrasonics</i> (2001), 2020, 47, 511-520.	0.6	20
672	Plasma Long Noncoding RNA LeXis is a Potential Diagnostic Marker for Non-Alcoholic Steatohepatitis. <i>Life</i> , 2020, 10, 230.	1.1	8
673	Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. <i>Scientific Reports</i> , 2020, 10, 18345.	1.6	19
674	Association between noninvasive assessment of liver fibrosis and coronary artery calcification progression in patients with nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2020, 10, 18323.	1.6	21
675	Clinical endpoints are necessary in the interim analysis of REGENERATE. <i>Lancet, The</i> , 2020, 396, 663.	6.3	0
676	Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001189.	1.2	4
677	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <i>Diagnostics</i> , 2020, 10, 643.	1.3	12
678	Low Thyroid Function in Nonalcoholic Fatty Liver Disease Is an Independent Predictor of All-Cause and Cardiovascular Mortality. <i>American Journal of Gastroenterology</i> , 2020, 115, 1496-1504.	0.2	40
679	A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. <i>Cells</i> , 2020, 9, 2014.	1.8	27
680	Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Advances in Therapy</i> , 2020, 37, 4697-4708.	1.3	81
681	The marine compound and elongation factor 1A1 inhibitor, didemnin B, provides benefit in western diet-induced non-alcoholic fatty liver disease. <i>Pharmacological Research</i> , 2020, 161, 105208.	3.1	8
682	A composite biomarker using multiparametric magnetic resonance imaging and blood analytes accurately identifies patients with non-alcoholic steatohepatitis and significant fibrosis. <i>Scientific Reports</i> , 2020, 10, 15308.	1.6	31
683	Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00177.	1.0	10
684	Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). <i>Diabetologia</i> , 2020, 63, 2434-2445.	2.9	115
685	Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E863-E876.	1.8	21
686	<p>Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data<p>. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 115-123.	0.9	13
687	Ultrasound-based liver elastography: current results and future perspectives. <i>Abdominal Radiology</i> , 2020, 45, 3463-3472.	1.0	20

#	ARTICLE	IF	CITATIONS
688	Noninvasive Tests (NITs) for Hepatic Fibrosis in Fatty Liver Syndrome. <i>Life</i> , 2020, 10, 198.	1.1	11
689	Transient elastography with controlled attenuation parameter (CAP) for diagnosis of moderate or severe steatosis in people with suspected non-alcoholic fatty liver disease. <i>The Cochrane Library</i> , 0, , .	1.5	2
690	Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice. <i>Hepatology Communications</i> , 2020, 4, 1441-1458.	2.0	23
691	Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap. <i>Current Hepatology Reports</i> , 2020, 19, 382-390.	0.4	0
692	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	1.2	8
693	C-Peptide: A Mediator of the Association Between Serum Uric Acid to Creatinine Ratio and Non-Alcoholic Fatty Liver Disease in a Chinese Population With Normal Serum Uric Acid Levels. <i>Frontiers in Endocrinology</i> , 2020, 11, 600472.	1.5	15
694	Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. <i>Frontiers in Pharmacology</i> , 2020, 11, 603926.	1.6	115
695	Cigarette Smoking Increased Risk of Overall Mortality in Patients With Non-alcoholic Fatty Liver Disease: A Nationwide Population-Based Cohort Study. <i>Frontiers in Medicine</i> , 2020, 7, 604919.	1.2	19
696	New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. <i>Frontiers in Pediatrics</i> , 2020, 8, 603654.	0.9	23
697	Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients. <i>JGH Open</i> , 2020, 4, 1155-1161.	0.7	2
698	Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?. <i>Nutrients</i> , 2020, 12, 3363.	1.7	16
699	Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial. <i>Nutrients</i> , 2020, 12, 3372.	1.7	19
700	Obeticholic acid for treatment of NAFLD—A drug in search of a disease. <i>GastroHep</i> , 2020, 2, 133-137.	0.3	3
701	Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study. <i>Cardiovascular Diabetology</i> , 2020, 19, 51.	2.7	52
702	Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 739-752.	3.7	481
703	La stéatopathie dysmétabolique ou NASH: faut-il dépister les patients à haut risque atteints de diabète de type 2 ou d'obésité?. <i>Nutrition Clinique Et Metabolisme</i> , 2020, 34, 122-129.	0.2	0
704	Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice. <i>Scientific Reports</i> , 2020, 10, 7440.	1.6	8
705	Expression of the Long Noncoding RNA GAS5 Correlates with Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Genes</i> , 2020, 11, 545.	1.0	27

#	ARTICLE	IF	CITATIONS
706	Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1149-1159.	1.9	101
707	Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092390.	1.4	24
708	Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 9.	1.3	60
709	Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154291.	1.5	20
710	Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?. <i>Cancers</i> , 2020, 12, 1422.	1.7	41
711	PPAR β gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 894-904.	0.7	2
712	HIV and antiretroviral therapy-related fat alterations. <i>Nature Reviews Disease Primers</i> , 2020, 6, 48.	18.1	104
713	Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 623-632.	1.9	67
714	Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. <i>Atherosclerosis</i> , 2020, 299, 32-37.	0.4	21
715	Nonalcoholic Fatty Liver Disease. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	0.9	6
716	Epidemiology of non-alcoholic fatty liver disease in Asia. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 1-8.	0.7	39
717	Treatment of non-alcoholic fatty liver disease – Current perspectives. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 22-31.	0.7	18
718	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
719	Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1328-1338.	2.2	26
720	Nonalcoholic Steatohepatitis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1175.	3.8	784
721	The Effect of Moderate Weight Loss on a Non-Invasive Biomarker of Liver Fibrosis: A Randomised Controlled Trial. <i>Obesity Facts</i> , 2020, 13, 144-151.	1.6	3
722	Obeticholic acid for the treatment of nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 311-321.	1.4	30
723	Characterization of the immune cell landscape of patients with NAFLD. <i>PLoS ONE</i> , 2020, 15, e0230307.	1.1	46

#	ARTICLE	IF	CITATIONS
724	Relationship between Heart Disease and Liver Disease: A Two-Way Street. <i>Cells</i> , 2020, 9, 567.	1.8	77
725	Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. <i>Hypertension</i> , 2020, 76, 562-568.	1.3	39
726	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 513-526.	1.9	66
727	Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. <i>Journal of Hepatology</i> , 2020, 73, 1023-1029.	1.8	108
728	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 159, 1839-1852.	0.6	103
729	Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers. <i>Journal of the Neurological Sciences</i> , 2020, 416, 116981.	0.3	4
730	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 527-547.	1.0	5
731	Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis. <i>Annals of Surgery</i> , 2020, 272, 32-39.	2.1	40
732	Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score. <i>Hepatology Communications</i> , 2020, 4, 998-1011.	2.0	7
733	Developmental changes in hepatic lipid metabolism of chicks during the embryonic periods and the first week of posthatch. <i>Poultry Science</i> , 2020, 99, 1655-1662.	1.5	16
734	Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. <i>Disease Markers</i> , 2020, 2020, 1-7.	0.6	10
735	The metabolic basis of nonalcoholic steatohepatitis. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00112.	1.0	64
736	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0219412.	1.1	17
737	Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. <i>JGH Open</i> , 2020, 4, 497-502.	0.7	22
738	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154183.	1.5	39
739	Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 2671.	1.6	28
740	A Microbial Signature Identifies Advanced Fibrosis in Patients with Chronic Liver Disease Mainly Due to NAFLD. <i>Scientific Reports</i> , 2020, 10, 2771.	1.6	44
741	Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 105-121.	1.0	4

#	ARTICLE	IF	CITATIONS
742	Application of nanosensors in the food industry. , 2020, , 355-368.		12
743	A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Reports, 2020, 2, 100064.	2.6	29
744	Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Translational Gastroenterology and Hepatology, 2020, 5, 16-16.	1.5	296
745	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology, 2020, 158, 1851-1864.	0.6	710
746	Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. American Journal of Roentgenology, 2020, 214, 786-791.	1.0	20
747	Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1579-1589.	1.4	27
748	Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. Alimentary Pharmacology and Therapeutics, 2020, 51, 388-396.	1.9	22
749	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, 2020, 72, 892-905.	3.6	227
750	Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity. Scientific Reports, 2020, 10, 1025.	1.6	9
751	Four-And-A-Half LIM-Domain Protein 2 (FHL2) Deficiency Aggravates Cholestatic Liver Injury. Cells, 2020, 9, 248.	1.8	9
752	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. Hepatology, 2020, 72, 1230-1241.	3.6	59
753	Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects. Scientific Reports, 2020, 10, 983.	1.6	48
754	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-10.	0.8	40
756	Impact of using different biomarkers of liver fibrosis on hepatologic referral of individuals with severe obesity and NAFLD. Journal of Endocrinological Investigation, 2020, 43, 1019-1026.	1.8	13
757	Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154170.	1.5	278
758	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 362-373.	3.7	411
759	Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?. Annals of Hepatology, 2020, 19, 258-264.	0.6	9
760	Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea. BMC Cardiovascular Disorders, 2020, 20, 204.	0.7	18

#	ARTICLE	IF	CITATIONS
761	Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. <i>Metabolites</i> , 2020, 10, 168.	1.3	26
762	Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. <i>PLoS Medicine</i> , 2020, 17, e1003100.	3.9	205
763	Association between high dose catecholamine support and liver dysfunction following cardiac surgery. <i>Journal of Cardiac Surgery</i> , 2020, 35, 1228-1236.	0.3	5
764	Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 1620-1633.	1.9	20
765	Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. <i>Journal of Clinical Medicine</i> , 2020, 9, 1065.	1.0	21
766	Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. <i>Journal of Internal Medicine</i> , 2020, 288, 139-151.	2.7	145
767	Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. <i>European Journal of Medicinal Chemistry</i> , 2020, 197, 112311.	2.6	10
768	Prevalence and risk factors of fatty liver in Portuguese adults. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13235.	1.7	7
769	Non-invasive diagnosis of patients with "at-risk" NAFLD : only fibrosis counts?. <i>Gut</i> , 2020, 69, 1164-1165.	6.1	7
770	Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. <i>Cells</i> , 2020, 9, 875.	1.8	516
771	Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 1032.	1.0	33
772	Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 136-145.e6.	2.4	47
773	Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. <i>Frontline Gastroenterology</i> , 2021, 12, 102-107.	0.9	8
774	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5.	2.4	90
775	Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 384-390.e1.	2.4	60
776	Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. <i>Cell Biology and Toxicology</i> , 2021, 37, 293-311.	2.4	25
777	Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. <i>Digestive and Liver Disease</i> , 2021, 53, 79-85.	0.4	36
778	Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 219-231.e1.	0.6	167

#	ARTICLE	IF	CITATIONS
779	Liver fibrosis: Pathophysiology and clinical implications. <i>WIREs Mechanisms of Disease</i> , 2021, 13, e1499.	1.5	61
780	Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , 2021, 20, 100253.	0.6	21
781	Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. <i>Gut</i> , 2021, 70, 1375-1382.	6.1	307
782	Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107747.	1.2	9
783	NAFLD-related mortality: simple hepatic steatosis is not as "benign" as thought. <i>Gut</i> , 2021, 70, 1212-1213.	6.1	22
784	Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease. <i>Acta Diabetologica</i> , 2021, 58, 319-327.	1.2	4
785	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 125-134.	2.5	3
786	Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 811-818.	1.8	55
787	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 552-560.	1.1	7
788	Maladaptive regeneration "the reawakening of developmental pathways" in NASH and fibrosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 131-142.	8.2	64
789	Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD. <i>Hepatology</i> , 2021, 73, 2196-2205.	3.6	25
790	Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. <i>Frontiers in Immunology</i> , 2020, 11, 609900.	2.2	16
791	Development and validation of a noninvasive clinical scoring system to predict significant fibrosis in patients with nonalcoholic fatty liver disease. <i>Clinica Chimica Acta</i> , 2021, 514, 48-53.	0.5	2
792	Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. <i>Molecular Metabolism</i> , 2021, 46, 101153.	3.0	10
793	Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. <i>Hepatology Communications</i> , 2021, 5, 158-167.	2.0	41
794	The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States. <i>Hepatology Communications</i> , 2021, 5, 83-96.	2.0	15
795	Regulation of the cytochrome P450 epoxygenase pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102229.	1.0	6
796	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e34-e44.	1.8	13

#	ARTICLE	IF	CITATIONS
797	NAFLD: Reporting Histologic Findings in Clinical Practice. <i>Hepatology</i> , 2021, 73, 2028-2038.	3.6	86
798	Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1623-1631.	1.9	37
799	5-HT2B Receptors in Liver. <i>Receptors</i> , 2021, , 247-264.	0.2	0
800	A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4046-4057.	1.1	3
801	Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice. <i>Endocrine Journal</i> , 2021, 68, 743-749.	0.7	2
802	Response to letter: Multiparametric magnetic resonance imaging in patients with nonalcoholic fatty liver disease. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1941-1941.	1.9	0
803	Non-invasive markers of liver fibrosis and outcome in large vessel occlusion stroke. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110372.	1.5	19
804	Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study. <i>Cardiovascular Diabetology</i> , 2021, 20, 8.	2.7	28
805	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. <i>Diagnostics</i> , 2021, 11, 98.	1.3	59
806	SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH. <i>Hepatology Communications</i> , 2021, 5, 760-773.	2.0	38
807	The early identification of alcohol use disorders and liver injury: proposal for a diagnostic algorithm. <i>Panminerva Medica</i> , 2021, 63, 361-367.	0.2	16
808	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. <i>Journal of Clinical Medicine</i> , 2021, 10, 467.	1.0	31
809	Impact of Obesity in Non-Alcoholic Fatty Liver Disease. <i>Journal of Biomedical Science and Engineering</i> , 2021, 14, 21-32.	0.2	1
810	Nutraceuticals for Non-alcoholic Fatty Liver Disease. <i>Contemporary Cardiology</i> , 2021, , 141-165.	0.0	1
811	Reply to "Multiparametric MRI in patients with nonalcoholic fatty liver disease". <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1940-1940.	1.9	0
812	The Role of Transient Elastography in NAFLD. , 2021, , 61-74.		0
813	Early kidney dysfunction in non-alcoholic fatty liver disease - is transient elastography useful as a screening method?. <i>Digestive Diseases</i> , 2021, 39, 653-662.	0.8	1
814	Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study. <i>BMC Gastroenterology</i> , 2021, 21, 25.	0.8	4

#	ARTICLE	IF	CITATIONS
815	Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact. <i>Processes</i> , 2021, 9, 135.	1.3	62
816	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. <i>Clinical Liver Disease</i> , 2021, 17, 19-22.	1.0	31
817	Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 44-57.	4.5	38
819	Nonalcoholic Fatty Liver Disease and Fibrosis Risk in Patients With Obstructive Sleep Apnea: A Retrospective Analysis. <i>Cureus</i> , 2021, 13, e13623.	0.2	1
820	Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. <i>Nutrients</i> , 2021, 13, 604.	1.7	7
821	Development of a Non-Invasive Liver Fibrosis Score Based on Transient Elastography for Risk Stratification in Patients with Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 2021, 36, 134-145.	1.3	7
822	Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, , .	0.6	6
823	Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0245762.	1.1	61
824	Therapeutic pipeline in nonalcoholic steatohepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 373-392.	8.2	173
825	How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?. <i>Hepatology International</i> , 2021, 15, 21-35.	1.9	137
826	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e018869.	1.6	20
827	Valoraci3n bioqu3mica en la enfermedad hep3tica grasa asociada a la disfunci3n metab3lica. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 209-219.	0.1	1
828	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 437-442.	0.6	4
829	Cognitive Dysfunction in Non-Alcoholic Fatty Liver Diseaseâ€”Current Knowledge, Mechanisms and Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 673.	1.0	51
830	From the origin of NASH to the future of metabolic fatty liver disease. <i>Gut</i> , 2021, 70, 1570-1579.	6.1	43
831	An update on drug development for the treatment of nonalcoholic fatty liver disease â€” from ongoing clinical trials to future therapy. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 333-340.	1.3	20
832	3D human nonalcoholic hepatic steatosis and fibrosis models. <i>Bio-Design and Manufacturing</i> , 2021, 4, 157-170.	3.9	20
833	Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Exploration of Medicine</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
834	Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 2858.	1.6	16
835	Use of noninvasive scores for advanced liver fibrosis can guide the need for hepatic biopsy during bariatric procedures. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 292-298.	1.0	10
837	Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications. <i>Current Diabetes Reports</i> , 2021, 21, 8.	1.7	27
838	Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. <i>Antioxidants</i> , 2021, 10, 270.	2.2	104
839	The Association Between Different Obesity Phenotypes and Liver Fibrosis Scores in Elderly Individuals with Fatty Liver in Taiwan. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1473-1483.	1.1	3
840	Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinical Therapeutics</i> , 2021, 43, 455-472.	1.1	8
841	Coupling Machine Learning and Lipidomics as a Tool to Investigate Metabolic Dysfunction-Associated Fatty Liver Disease. A General Overview. <i>Biomolecules</i> , 2021, 11, 473.	1.8	10
842	Opportunistic Screening at Abdominal CT: Use of Automated Body Composition Biomarkers for Added Cardiometabolic Value. <i>Radiographics</i> , 2021, 41, 524-542.	1.4	53
843	A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. <i>Nutrients</i> , 2021, 13, 914.	1.7	6
844	Fatty Liver Index and Development of Cardiovascular Disease: Findings from the UK Biobank. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2092-2100.	1.1	30
845	The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 930.	1.0	6
846	Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?. <i>Hepatology International</i> , 2021, 15, 380-391.	1.9	42
847	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	3.7	130
848	Identifying Advanced Fibrosis in NAFLD Using Noninvasive Tests. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, .	1.1	2
849	Proteomics analysis of adipose depots after intermittent fasting reveals visceral fat preservation mechanisms. <i>Cell Reports</i> , 2021, 34, 108804.	2.9	24
850	Hepatic lymphocytes involved in the pathogenesis of pediatric and adult non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 5129.	1.6	17
851	Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1379-1388.	1.1	9
852	Biochemical assessment of metabolic associated fatty liver disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 199-208.	0.1	3

#	ARTICLE	IF	CITATIONS
853	Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	0.8	11
854	Simple noninvasive scoring systems and histological scores in predicting mortality in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1754-1768.	1.4	5
855	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. <i>Gut</i> , 2022, 71, 778-788.	6.1	132
856	Clinical characteristics and risk factors of nonalcoholic fatty liver disease in children with obesity. <i>BMC Pediatrics</i> , 2021, 21, 122.	0.7	22
857	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. <i>Scientific Reports</i> , 2021, 11, 5416.	1.6	12
858	Utility of Multiparametric CT for Identification of High-Risk NAFLD. <i>American Journal of Roentgenology</i> , 2021, 216, 659-668.	1.0	11
859	Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?. <i>Clinical Liver Disease</i> , 2021, 17, 215-219.	1.0	1
860	Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 173-180.	0.6	15
861	Natural History of NAFLD. <i>Journal of Clinical Medicine</i> , 2021, 10, 1161.	1.0	23
862	Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. <i>BMC Gastroenterology</i> , 2021, 21, 135.	0.8	8
863	Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis. <i>Nutrition Research</i> , 2021, 88, 34-43.	1.3	5
864	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. <i>Frontiers in Medicine</i> , 2021, 8, 615978.	1.2	88
865	Activation of thyroid hormone receptor α 2 improved disease activity and metabolism independent of body weight in a mouse model of nonalcoholic steatohepatitis and fibrosis. <i>British Journal of Pharmacology</i> , 2021, 178, 2412-2423.	2.7	47
867	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Diagnostics</i> , 2021, 11, 787.	1.3	12
868	The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD). <i>PLoS ONE</i> , 2021, 16, e0249614.	1.1	15
869	Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin. <i>Gastroenterology Insights</i> , 2021, 12, 155-165.	0.7	12
870	Triglycerides to high-density lipoprotein cholesterol ratio for diagnosing nonalcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	6
871	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , 2021, 38, 2130-2158.	1.3	46

#	ARTICLE	IF	CITATIONS
872	Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools—a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 727-727.	0.7	3
873	Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH. <i>Molecular Metabolism</i> , 2021, 46, 101178.	3.0	41
874	Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 221-235.	4.5	30
875	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2022, 71, 983-990.	6.1	45
876	Effect of Central Corticotropin-Releasing Factor on Hepatic Lipid Metabolism and Inflammation-Related Gene Expression in Rats. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3940.	1.8	5
877	Association of obstructive sleep apnea with non-alcoholic fatty liver disease in patients with obesity: an observational study. <i>Eating and Weight Disorders</i> , 2021, , 1.	1.2	6
878	Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease Using Noninvasive Tests From Primary Care and Endocrinology Real-World Practices. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00340.	1.3	15
879	NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2856-e2865.	1.8	26
880	Liver stiffness: a motivational tool for achieving alcohol abstinence in alcohol use disorder patients?. <i>Minerva Gastroenterology</i> , 2021, 67, 299-300.	0.3	4
881	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. <i>BMC Gastroenterology</i> , 2021, 21, 180.	0.8	5
882	Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development. <i>Nutrients</i> , 2021, 13, 1442.	1.7	85
883	Diagnostic accuracy of fibrosis tests in children with non-alcoholic fatty liver disease: A systematic review. <i>Liver International</i> , 2021, 41, 2087-2100.	1.9	16
884	On the Proposed Definition of Metabolic-Associated Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 865-870.	2.4	33
885	PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity. <i>Nutrients</i> , 2021, 13, 1621.	1.7	8
886	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. <i>Seminars in Liver Disease</i> , 2021, 41, 235-247.	1.8	4
887	Longitudinal Effect of Hemoglobin Concentration With Incident Ischemic Heart Disease According to Hepatic Steatosis Status Among Koreans. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 677040.	1.1	3
888	The role of elastography in non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2021, 67, 164-170.	0.3	7
889	Preliminary experience with 3T magnetic resonance elastography imaging of the liver. <i>South African Journal of Radiology</i> , 2021, 25, 2072.	0.1	0

#	ARTICLE	IF	CITATIONS
890	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
891	Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107885.	1.2	7
892	Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) – Rather a Bystander Than a Driver of Mortality. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 2670-2677.	1.8	29
893	FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2415.	1.0	24
894	Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Diabetes Therapy</i> , 2021, 12, 1735-1749.	1.2	16
895	Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396.	1.4	6
896	Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e25327.	0.4	3
897	Animal Fat Intake Is Associated with Albuminuria in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome. <i>Nutrients</i> , 2021, 13, 1548.	1.7	6
898	Managing cardiometabolic risk factors across a woman's lifespan: A lipidologist's perspective. <i>Journal of Clinical Lipidology</i> , 2021, 15, 423-430.	0.6	5
899	Plasma and stool metabolomics to identify microbiota derived-biomarkers of metabolic dysfunction-associated fatty liver disease: effect of PNPLA3 genotype. <i>Metabolomics</i> , 2021, 17, 58.	1.4	10
900	Health disparities in cardiometabolic risk among Black and Hispanic youth in the United States. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100175.	1.3	18
901	New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3957-e3968.	1.8	10
902	Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. <i>International Journal of Obesity</i> , 2021, 45, 2197-2204.	1.6	21
903	Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?. <i>Pediatric Reports</i> , 2021, 13, 312-321.	0.5	10
904	Correlation Between Q_{ElaXto} Techniques and Supersonic Imagine for Liver Stiffness Quantification in Chronic Liver Disease. <i>Journal of Ultrasound in Medicine</i> , 2022, 41, 877-886.	0.8	5
905	Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease. <i>Hepatology International</i> , 2021, 15, 1148-1159.	1.9	14
906	LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 452-459.	0.6	14
907	Collagen VI as a driver and disease biomarker in human fibrosis. <i>FEBS Journal</i> , 2022, 289, 3603-3629.	2.2	37

#	ARTICLE	IF	CITATIONS
908	Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013156.	1.5	13
909	Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	3.6	102
910	Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Reports, 2021, 3, 100287.	2.6	2
911	FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis Validation in an Indian Cohort. Journal of Clinical and Experimental Hepatology, 2022, 12, 440-447.	0.4	9
912	Non-alcoholic fatty liver disease. Lancet, The, 2021, 397, 2212-2224.	6.3	1,035
913	Towards collaborative management of non-alcoholic fatty liver disease: a "real-world" pathway for fibrosis risk assessment in primary care. Internal Medicine Journal, 2022, 52, 1749-1758.	0.5	3
914	Pathology of non-alcoholic fatty liver disease. Pathologica, 2021, 113, 194-202.	1.3	17
915	Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury. Cells, 2021, 10, 1562.	1.8	12
916	Recent advances in nonalcoholic fatty liver disease metabolomics. Clinical and Molecular Hepatology, 2021, 27, 553-559.	4.5	40
917	Circulating Thrombospondin-2 as a Novel Fibrosis Biomarker of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes. Diabetes Care, 2021, 44, 2089-2097.	4.3	27
918	Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis. Clinical and Translational Gastroenterology, 2021, 12, e00371.	1.3	6
919	Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease—a realm for non-invasive testing. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 216-216.	1.9	0
920	Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. American Journal of Gastroenterology, 2021, 116, 1833-1841.	0.2	15
921	The needs of surveillance of metabolic associated fatty liver disease in Taiwan. Advances in Digestive Medicine, 2021, 8, 71-72.	0.1	0
922	Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999-2016. Chinese Medical Journal, 2021, 134, 1593-1601.	0.9	28
923	Low skeletal muscle mass is associated with liver fibrosis in individuals with type 2 diabetes and nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3204-3211.	1.4	8
924	Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. Liver International, 2021, 41, 2590-2600.	1.9	10
925	Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. International Journal of Eating Disorders, 2021, 54, 2025-2030.	2.1	5

#	ARTICLE	IF	CITATIONS
926	Usefulness of FibroScan-AST (FAST) score in Japanese patients with non-alcoholic fatty liver disease: A single-center retrospective experience. <i>Acta Hepatologica Japonica</i> , 2021, 62, 393-402.	0.0	0
927	Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108922.	1.1	5
928	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013157.	1.5	7
929	Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108884.	1.1	15
930	PRO-C3, a Serological Marker of Fibrosis, During Childhood and Correlations With Fibrosis in Pediatric NAFLD. <i>Hepatology Communications</i> , 2021, 5, 1860-1872.	2.0	4
931	Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2022, 16, 290-299.	1.4	37
932	Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108879.	1.1	8
933	Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis. <i>Frontiers in Medicine</i> , 2021, 8, 698502.	1.2	5
934	A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. <i>Cells</i> , 2021, 10, 1822.	1.8	24
935	Preparing for the NASH Epidemic: A Call to Action. <i>Diabetes Care</i> , 2021, 44, 2162-2172.	4.3	30
936	Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. <i>Digestive and Liver Disease</i> , 2021, 53, 866-872.	0.4	22
937	Prevalence and risk factors of steatosis and advanced fibrosis using transient elastography in the United States™ adolescent population. <i>World Journal of Hepatology</i> , 2021, 13, 790-803.	0.8	1
938	Racial differences in prevalence and severity of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2021, 13, 763-773.	0.8	15
939	Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis. <i>American Journal of Gastroenterology</i> , 2021, 116, 2258-2269.	0.2	25
940	Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. <i>Liver International</i> , 2021, 41, 1999-2008.	1.9	7
941	Prospective assessment of liver stiffness by shear wave elastography in childhood obesity: a pilot study. <i>Endocrine</i> , 2022, 75, 59-69.	1.1	6
942	Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease. <i>Magnetic Resonance Imaging</i> , 2021, 80, 1-8.	1.0	15
943	AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects. <i>Scientific Reports</i> , 2021, 11, 14834.	1.6	24

#	ARTICLE	IF	CITATIONS
944	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 363-401.	4.5	152
945	Editorial: an elastography-based two-step approach to detect NAFLD with compensated advanced chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 515-516.	1.9	1
946	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
947	Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. <i>Seminars in Liver Disease</i> , 2021, 41, 421-434.	1.8	55
948	Effect of low carbohydrate diets on insulin resistance and the metabolic syndrome. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 463-468.	1.2	8
949	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. <i>Internal Medicine</i> , 2021, 60, 2167-2174.	0.3	15
950	A Model Incorporating Serum Alkaline Phosphatase for Prediction of Liver Fibrosis in Adults with Obesity and Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 3311.	1.0	4
951	Liver Fibrosis is Associated with Ischemic Stroke Risk in Women but not Men: The REGARDS Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105788.	0.7	15
952	Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2402-2408.	2.2	10
953	More promising results of liver intravoxel incoherent motion imaging analysis for the assessment of nonalcoholic steatohepatitis and fibrosis. <i>Annals of Translational Medicine</i> , 2021, 9, 1283-1283.	0.7	1
954	Decline in serum albumin concentration is a predictor of serious events in nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2021, 100, e26835.	0.4	21
955	Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 2399-2409.	0.2	9
956	Oxy210, a novel inhibitor of hedgehog and TGF α ² signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00296.	1.0	13
957	Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. <i>Hepatology</i> , 2021, 74, 2410-2423.	3.6	91
958	Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. <i>PLoS ONE</i> , 2021, 16, e0255822.	1.1	5
959	Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1013-1025.	1.9	47
960	A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3676-3688.	1.1	11
961	Evaluating causality of cellular senescence in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2021, 3, 100301.	2.6	30

#	ARTICLE	IF	CITATIONS
962	Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2021, 300, 361-368.	3.6	11
963	Epidemiology and risk-stratification of NAFLD-associated HCC. <i>Journal of Hepatology</i> , 2021, 75, 1476-1484.	1.8	160
965	The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 878-887.	0.9	9
966	Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 471-480.	0.6	9
967	Non-alcoholic fatty liver disease: time for changes. <i>Mã-Å¼narodnij Endokrinologã-Änij Å½urnal</i> , 2021, 17, 334-345.	0.1	3
968	Embedding assessment of liver fibrosis into routine diabetic review in primary care. <i>JHEP Reports</i> , 2021, 3, 100293.	2.6	23
969	Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. <i>Clinical Therapeutics</i> , 2021, 43, 1505-1522.	1.1	6
970	Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 15938.	1.6	21
971	Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. <i>Metabolism: Clinical and Experimental</i> , 2021, 121, 154796.	1.5	3
972	Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0255535.	1.1	8
973	Hepatic sexual dimorphism â€” implications for non-alcoholic fatty liver disease. <i>Nature Reviews Endocrinology</i> , 2021, 17, 662-670.	4.3	41
974	Preparing for the NASH epidemic: A call to action. <i>Obesity</i> , 2021, 29, 1401-1412.	1.5	7
975	Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm. <i>Digestive Diseases</i> , 2022, 40, 644-653.	0.8	3
976	What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?. <i>Hepatology Communications</i> , 2021, 5, 1810-1823.	2.0	18
977	Comprehensive Analysis of NAFLD and the Therapeutic Target Identified. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 704704.	1.8	13
978	Preparing for the NASH Epidemic: A Call to Action. <i>Gastroenterology</i> , 2021, 161, 1030-1042.e8.	0.6	58
979	Prevalence and predictors of non-alcoholic fatty liver disease in tertiary care hospital of Taif, Saudi Arabia: A retrospective study. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4921-4925.	1.8	4
980	Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2021, 45, 739-752.	1.8	16

#	ARTICLE	IF	CITATIONS
981	Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. <i>European Journal of Pharmacology</i> , 2021, 907, 174272.	1.7	14
982	Magnetic resonance elastography plus Fibrosis ⁴ versus FibroScan ⁴ aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	3.6	29
983	Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. <i>Gut</i> , 2022, 71, 1867-1875.	6.1	105
984	Association between Fasting Ketonuria and Advanced Liver Fibrosis in Non-Alcoholic Fatty Liver Disease Patients without Prediabetes and Diabetes Mellitus. <i>Nutrients</i> , 2021, 13, 3400.	1.7	6
985	Preparing for the NASH epidemic: A call to action. <i>Metabolism: Clinical and Experimental</i> , 2021, 122, 154822.	1.5	25
986	Non-alcoholic fatty liver disease and hematologic manifestations (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1355.	0.8	4
987	Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. <i>Radiology</i> , 2021, 301, 625-634.	3.6	20
988	Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus. <i>Annals of Palliative Medicine</i> , 2021, 10, 9702-9714.	0.5	2
989	The association of hepatic steatosis and fibrosis with heart failure and mortality. <i>Cardiovascular Diabetology</i> , 2021, 20, 197.	2.7	29
990	Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. <i>Cardiovascular Diabetology</i> , 2021, 20, 193.	2.7	17
991	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α), versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1263-1277.	1.9	90
992	NAFLD in the Elderly. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 1633-1649.	1.3	43
993	Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. <i>European Radiology</i> , 2022, 32, 1781-1791.	2.3	8
994	Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. , 2021, 32, 661-666.		4
995	Coronary CT Angiography in Asymptomatic Adults with Hepatic Steatosis. <i>Radiology</i> , 2021, 301, 593-601.	3.6	2
997	Screening for nonalcoholic fatty liver disease-when, who and how?. <i>World Journal of Gastroenterology</i> , 2021, 27, 5803-5821.	1.4	18
998	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 903-913.	3.7	227
999	Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154874.	1.5	20

#	ARTICLE	IF	CITATIONS
1000	Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1703-1713.	1.4	12
1001	Non-alcoholic Fatty Liver and Liver Fibrosis Predictive Analytics: Risk Prediction and Machine Learning Techniques for Improved Preventive Medicine. <i>Journal of Medical Systems</i> , 2021, 45, 22.	2.2	10
1002	Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-11.	0.8	17
1003	MR Elastography. , 2021, , 1759-1774.		0
1004	Sleeve Gastrectomy in Non-alcoholic Steatohepatitis (NASH) and Liver Cirrhosis. , 2021, , 115-137.		0
1005	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. <i>Nutrients</i> , 2021, 13, 169.	1.7	9
1006	High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China. <i>Annals of Medicine</i> , 2021, 53, 1621-1631.	1.5	7
1007	Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	3
1008	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 417-440.	0.8	21
1009	Psychological Biomarker Profile in NAFLD/NASH with Advanced Fibrosis. , 2020, , 205-223.		8
1010	Non-Alcoholic Fatty Liver Disease. <i>Advances in Experimental Medicine and Biology</i> , 2017, 960, 443-467.	0.8	183
1011	The Natural History of NAFLD: Environmental vs. Genetic Risk Factors. , 2020, , 129-145.		2
1012	Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020, 55, 731-741.	2.3	22
1013	Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH). <i>Current Hepatology Reports</i> , 2020, 19, 63-69.	0.4	7
1014	Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2018, , 369-390.e14.		2
1016	Fatty liver disease and primary liver cancer: disease mechanisms, emerging therapies and the role of bariatric surgery. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 107-110.	1.9	7
1017	A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1420-1426.	0.8	4
1018	Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, 98-103.	0.8	33

#	ARTICLE	IF	CITATIONS
1021	Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 728-736.	1.9	104
1022	Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1030-1037.	1.9	40
1023	Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease. <i>Pediatric Obesity</i> , 2018, 13, 23-29.	1.4	19
1024	Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000904.	1.2	71
1025	High-trans fatty acid and high-sugar diets can cause mice with non-alcoholic steatohepatitis with liver fibrosis and potential pathogenesis. <i>Nutrition and Metabolism</i> , 2020, 17, 40.	1.3	11
1027	Association Between Renal Dysfunction and Major Adverse Cardiac Events After Liver Transplantation: Evidence from an International Randomized Trial of Everolimus-Based Immunosuppression. <i>Annals of Transplantation</i> , 2018, 23, 751-757.	0.5	19
1028	Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. <i>PLoS ONE</i> , 2016, 11, e0147237.	1.1	48
1029	Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. <i>PLoS ONE</i> , 2016, 11, e0167776.	1.1	17
1030	Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population. <i>PLoS ONE</i> , 2017, 12, e0173855.	1.1	14
1031	A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. <i>PLoS ONE</i> , 2017, 12, e0175717.	1.1	46
1032	Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0177249.	1.1	22
1033	Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2017, 12, e0182202.	1.1	26
1034	Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2018, 13, e0199166.	1.1	28
1035	Serum zinc level and hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0240195.	1.1	14
1036	Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. <i>PLoS ONE</i> , 2020, 15, e0241357.	1.1	4
1037	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. <i>PLoS ONE</i> , 2020, 15, e0241770.	1.1	20
1038	Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2017, XX, 1-11.	0.7	51
1039	Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 217-221.	0.7	38

#	ARTICLE	IF	CITATIONS
1040	Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. <i>Journal of Clinical and Translational Hepatology</i> , 2019, X, 1-11.	0.7	90
1041	The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases. <i>Hepatology Forum</i> , 2020, , 8-13.	0.3	27
1042	Fighting liver fat. <i>Endocrine Connections</i> , 2020, 9, R173-R186.	0.8	4
1043	Non-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 260-271.	0.5	9
1044	Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 427-431.	0.5	32
1045	Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 289-296.	0.5	11
1046	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245.	0.5	11
1048	Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 270-274.	0.1	2
1049	Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in chinese adults: a large population-based study. <i>Oncotarget</i> , 2016, 7, 14241-14250.	0.8	6
1050	Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?. <i>Current Pharmaceutical Design</i> , 2020, 26, 1036-1044.	0.9	24
1051	Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3909-3914.	0.9	7
1052	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.	0.9	3
1053	Non-Alcoholic Fatty Liver Disease and Vascular Disease. <i>Current Vascular Pharmacology</i> , 2020, 19, 269-279.	0.8	12
1054	Non-alcoholic fatty liver disease: prevalence, etiology, pathogenesis, approaches to the diagnosis and therapy (literature review and own data). <i>MAĵnarodnij EndokrinologĀĀnij Āĵurnal</i> , 2018, 14, 684-693.	0.1	2
1055	High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, 519-525.	4.3	102
1056	Alcoholic liver fibrosis: detection and treatment. <i>Minerva Medica</i> , 2018, 109, 457-471.	0.3	37
1057	NAFLD: comorbidity and associated diseases. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2020, 1, 57-65.	0.1	14
1058	Association between Atrial Fibrillation and Advanced Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>Yonsei Medical Journal</i> , 2020, 61, 860.	0.9	14

#	ARTICLE	IF	CITATIONS
1059	Application of transient elastography in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 128-141.	4.5	70
1060	The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 662-669.	4.5	34
1061	Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. <i>Cancers</i> , 2020, 12, 2778.	1.7	15
1062	Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events. <i>Middle East Journal of Digestive Diseases</i> , 2020, 12, 65-88.	0.2	6
1063	Perspectives of nonalcoholic fatty liver disease research: a personal point of view. , 2020, 1, 85-107.		23
1064	Endocrine causes of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11053.	1.4	69
1065	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2018, 24, 1491-1506.	1.4	95
1066	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. <i>World Journal of Gastroenterology</i> , 2018, 24, 4835-4845.	1.4	31
1067	Role of cenicriviroc in the management of nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2018, 24, 5415-5417.	1.4	3
1068	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4959-4969.	1.4	13
1069	Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. <i>Endocrinology and Metabolism</i> , 2020, 35, 165.	1.3	30
1070	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , 2020, 35, 243-259.	1.3	23
1071	Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 2133-2142.	0.8	7
1072	Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 267.	1.8	28
1073	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , 2020, 44, 382.	1.8	46
1074	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. <i>World Journal of Hepatology</i> , 2020, 12, 378-388.	0.8	9
1075	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. <i>World Journal of Hepatology</i> , 2017, 9, 697.	0.8	8
1076	Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2019, 13, 658-668.	1.4	35

#	ARTICLE	IF	CITATIONS
1077	Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2020, 14, 168-178.	1.4	63
1078	Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. <i>Gut and Liver</i> , 2020, 14, 537-545.	1.4	38
1079	ÂNASH: A glance at the landscape of pharmacological treatment. <i>Annals of Hepatology</i> , 2016, 15, 673-81.	0.6	23
1080	Weight loss, insulin resistance, and study design confound results in a meta-analysis of animal models of fatty liver. <i>ELife</i> , 2020, 9, .	2.8	7
1081	Association between serum and dietary antioxidant micronutrients and advanced liver fibrosis in non-alcoholic fatty liver disease: an observational study. <i>PeerJ</i> , 2020, 8, e9838.	0.9	23
1082	Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. <i>Cureus</i> , 2020, 12, e10446.	0.2	17
1083	Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment. <i>Clinical Medicine</i> , 2020, 20, 313-318.	0.8	14
1084	Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. <i>International Journal of Medical Sciences</i> , 2021, 18, 3624-3630.	1.1	4
1085	The association between nonalcoholic fatty liver disease and cardiovascular disease: A window of opportunity. <i>Journal of Clinical and Preventive Cardiology</i> , 2021, 10, 112.	0.2	0
1086	Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110504.	1.4	15
1087	Mass Spectrometry-Based Proteomics in Alcoholic and Non-Alcoholic Steatohepatitis. , 2021, 07, .		0
1089	Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of nonâ€œalcoholic steatohepatitis. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13695.	1.7	24
1090	ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. <i>Nature Medicine</i> , 2021, 27, 1836-1848.	15.2	97
1091	Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?. <i>World Journal of Gastroenterology</i> , 2021, 27, 6522-6526.	1.4	4
1092	Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 329-338.	0.7	49
1093	Comorbidity of non-alcoholic fatty liver disease and cardiovascular disease: focus on ademetionine and ursodeoxycholic acid. <i>Medical Alphabet</i> , 2021, 1, 13-20.	0.0	1
1094	Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. <i>Cell Reports</i> , 2021, 37, 109897.	2.9	4
1095	Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101816.	0.7	22

#	ARTICLE	IF	CITATIONS
1096	Hypoxia-Inducible Factors as Key Players in the Pathogenesis of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. <i>Frontiers in Medicine</i> , 2021, 8, 753268.	1.2	11
1097	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 60-69.	0.6	3
1098	Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2451-2461.e3.	2.4	37
1099	Non-alcoholic fatty liver disease: modern approaches to diagnosis and treatment. <i>Årsrapport om Rossijskij Årskrift Terapevtičeskoj Praktiki</i> , 2021, 2, 18-29.	0.1	2
1100	Defining NASH from a Multi-Omics Systems Biology Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 4673.	1.0	9
1101	NON-ALCOHOLIC FATTY LIVER DISEASE OUTCOMES FUNNEL. <i>Farmakoekonomika</i> , 2015, 8, 14-19.	0.4	2
1102	Hepatic and Extrahepatic Malignancies in NAFLD. , 2016, , 271-290.		0
1103	Nonalcoholic Fatty Liver Disease: Clinical Features, Disease Modifiers, and Natural History. , 2016, , 183-194.		0
1104	Liver Transplantation for Nonalcoholic Fatty Liver Disease: Role of Bariatric Surgery for Comorbid Obesity. <i>Journal of Advanced Nutritional and Human Metabolism</i> , 0, , .	0.0	1
1105	Lipotoxicity in Non-parenchymal Liver Cells. , 2017, , 1-21.		0
1107	Development of a non-invasive model to improve the accuracy of determining liver fibrosis stage in Nonalcoholic fatty liver disease. <i>Gastroenterologia</i> , 2017, 51, 256-271.	0.0	1
1108	The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. <i>Sisli Etfal Hastanesi Tip Bulteni</i> , 2020, 54, 411-415.	0.1	4
1109	Systemic Review : Role of Lifestyle Interventions for the Treatment of Non-Alcoholic Fatty Liver Disease. <i>The Egyptian Journal of Hospital Medicine</i> , 2018, 70, 1421-1430.	0.0	0
1110	Non-Alcoholic Fatty Liver Disease. <i>The Egyptian Journal of Hospital Medicine</i> , 2018, 70, 570-576.	0.0	0
1111	Noninvasive Assessment of Disease Progression. , 2018, , 117-126.e3.		1
1112	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease. , 2018, , 391-405.e3.		1
1113	Epidemiology and Comorbidities. , 2018, , 1-83.		0
1114	Diagnostic Approach to Nonalcoholic Steatohepatitis. <i>Korean Journal of Medicine</i> , 2018, 93, 33-37.	0.1	1

#	ARTICLE	IF	CITATIONS
1116	The use of elastography in patients with chronic liver diseases. <i>Gastroenterologia</i> , 2018, 52, 98-103.	0.0	0
1117	Endogenous Intoxication Syndrome in Patients with Diabetes Mellitus in Combination with Nonalcoholic Fatty Liver Disease. <i>Ukraïns'kij Å¾urnal Medicini BÄologÄ Ta Sportu</i> , 2018, 3, 110-114.	0.0	0
1118	Future of pharmacological treatment of non-alcoholic steatohepatitis in terms of key pathophysiological mechanisms. <i>Vnitri Lekarstvi</i> , 2018, 64, 735-741.	0.1	0
1119	Elastography in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 5-13.	0.2	3
1120	MODERN NON-INVASIVE METHODS OF DIAGNOSTICS OF LIVER FIBROSIS IN CHILDREN. <i>Russian Pediatric Journal</i> , 2019, 20, 300-306.	0.0	3
1123	Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2020, 67, 274-282.	0.6	3
1124	MR Based-Imaging Biomarkers in NAFLD/NASH. , 2020, , 141-156.		0
1126	Relationship between non-alcoholic fatty liver disease and cardiovascular disease. <i>World Chinese Journal of Digestology</i> , 2020, 28, 313-329.	0.0	1
1127	GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. <i>Exploration of Medicine</i> , 2020, 1, 108-123.	1.5	3
1128	Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver DiseaseâA Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 283-298.	2.4	7
1129	Non-Alcoholic Fatty Liver Disease as a Coronary Heart Disease Severity Predictor. <i>International Journal of Clinical Medicine</i> , 2020, 11, 182-192.	0.1	2
1130	The Spectrum of NAFLD: From the Organ to the System. , 2020, , 1-10.		0
1131	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
1132	Detection of NAFLD/NASH in the General Population and in Primary Care Clinics. , 2020, , 11-27.		0
1133	BIOMARKERS OF CARDIOVASCULAR RISK IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. <i>Å½urnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta</i> , 2020, 18, 236-242.	0.0	0
1134	Part 1: Disease of the Heart and Liver. <i>Cardiology in Review</i> , 2022, 30, 111-122.	0.6	2
1135	What Is the Role of Bariatric Surgery in the Treatment of Nonalcoholic Steatohepatitis?. <i>Difficult Decisions in Surgery: an Evidence-based Approach</i> , 2021, , 201-211.	0.0	0
1136	Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 000, 1-11.	0.7	30

#	ARTICLE	IF	CITATIONS
1138	Obesity-Induced Cardiovascular Complications and Therapeutic Intervention. , 2020, , 15-53.		0
1139	Non-invasive Diagnostic Approach to NASH: Biological Markers. , 2020, , 235-256.		0
1141	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. , 2020, , 225-234.		0
1142	Comparison of knowledge and awareness between consultant physicians and resident doctors about non-alcoholic fatty liver disease. <i>Clinical and Experimental Hepatology</i> , 2020, 6, 374-383.	0.6	0
1144	Beneficial Effects of Honey Flavonoids in Nonalcoholic Fatty Liver Disease: An Update. , 2020, , 365-377.		0
1146	Enfermedad hepática grasa no alcohólica. <i>Medicine</i> , 2020, 13, 173-181.	0.0	0
1147	Pathological characterization of occult hepatitis B virus infection in hepatitis C virus-associated or non-alcoholic steatohepatitis-related hepatocellular carcinoma. <i>World Journal of Meta-analysis</i> , 2020, 8, 67-77.	0.1	0
1148	Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use. <i>Liver International</i> , 2022, 42, 350-362.	1.9	21
1149	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11905.	1.8	34
1150	Immune cell-mediated features of non-alcoholic steatohepatitis. <i>Nature Reviews Immunology</i> , 2022, 22, 429-443.	10.6	174
1152	Hepatocyte-derived exosomal miR-27a activates hepatic stellate cells through the inhibition of PINK1-mediated mitophagy in MAFLD. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1241-1254.	2.3	22
1153	Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge. <i>World Journal of Gastroenterology</i> , 2020, 26, 4018-4035.	1.4	5
1154	Non-alcoholic steatohepatitis and the risk of myocardial infarction: A population-based national study. <i>World Journal of Hepatology</i> , 2020, 12, 379-389.	0.8	0
1155	Liver Steatosis and NAFLD. <i>Medical Radiology</i> , 2021, , 251-265.	0.0	0
1156	Metabolic syndrome and cardiovascular pathology: focus on non-alcoholic fatty liver disease. <i>Ekspiermental'naya i Klinicheskaya Gastroenterologiya</i> , 2020, 183, 62-69.	0.1	0
1157	Estimation of visceral fat is useful for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2020, 26, 6658-6668.	1.4	12
1158	Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 2510-8.	0.0	13
1159	Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. <i>Gastroenterology and Hepatology</i> , 2016, 12, 756-763.	0.2	10

#	ARTICLE	IF	CITATIONS
1160	Application of Machine Learning Methods to Predict Non-Alcoholic Steatohepatitis (NASH) in Non-Alcoholic Fatty Liver (NAFL) Patients. AMIA ... Annual Symposium proceedings, 2018, 2018, 430-439.	0.2	20
1161	Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both?. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2019, 36, 64-71.	0.6	19
1162	Diagnostic and Treatment Implications of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Gastroenterology and Hepatology, 2019, 15, 83-89.	0.2	9
1163	Fatty liver disease in persons with HIV infection. Topics in Antiviral Medicine, 2019, 27, 75-82.	0.1	16
1164	Overview of Pediatric Nonalcoholic Fatty Liver Disease: A Guide for General Practitioners. Journal - Oklahoma State Medical Association, 2018, 111, 806-811.	0.4	2
1165	-diacetylcystine ameliorates inflammation in experimental non-alcoholic steatohepatitis by regulating nuclear transcription factor kappa B activation. International Journal of Clinical and Experimental Pathology, 2018, 11, 5351-5358.	0.5	1
1166	Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i. Hawai'i Journal of Health & Social Welfare, 2020, 79, 180-186.	0.2	0
1167	Changes and roles of intestinal fungal microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. American Journal of Translational Research (discontinued), 2020, 12, 3445-3460.	0.0	2
1168	Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver. Nagoya Journal of Medical Science, 2020, 82, 391-397.	0.6	3
1169	Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout. Medical Science Monitor, 2020, 26, e926187.	0.5	1
1170	Differential expression and bioinformatic analysis of circRNA in nonalcoholic steatohepatitis cirrhosis. International Journal of Clinical and Experimental Pathology, 2020, 13, 2820-2830.	0.5	0
1171	Smoking and Liver Disease. Gastroenterology and Hepatology, 2020, 16, 617-625.	0.2	3
1172	Bariatric Metabolic Surgery Reduced Liver Enzyme Levels in Patients with Non-Alcohol Fatty Liver Disease. Kansas Journal of Medicine, 2021, 14, 209-214.	0.1	0
1173	Liver Fibrosis Scoring Systems as Novel Tools for Predicting Recurrent Cardiovascular Events in Patients with a Prior Cardiovascular Event. Cardiology Discovery, 2021, 1, 214-222.	0.6	2
1174	Portal Venous Pulsatility Index as a predictor of fibrosis in patients with non-alcoholic fatty liver disease. Australasian Journal of Ultrasound in Medicine, 2022, 25, 36-41.	0.3	1
1175	PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD. BMC Gastroenterology, 2021, 21, 434.	0.8	8
1176	The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars in Liver Disease, 2022, 42, 034-047.	1.8	8
1177	Health Disparities in Cancer Among American Indians and Alaska Natives. Academic Radiology, 2022, 29, 1013-1021.	1.3	12

#	ARTICLE	IF	CITATIONS
1178	Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. <i>World Journal of Hepatology</i> , 2021, 13, 1584-1610.	0.8	20
1179	Fatty Liver Disease: Diagnosis and Stratification. <i>Annual Review of Medicine</i> , 2022, 73, 529-544.	5.0	17
1180	Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 146-161.	0.4	17
1181	Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO- α 1(I)NP3). <i>Liver International</i> , 2022, 42, 92-101.	1.9	12
1182	Ability of a Combined FIB4/miRNA181a Score to Predict Significant Liver Fibrosis in NAFLD Patients. <i>Biomedicines</i> , 2021, 9, 1751.	1.4	4
1183	Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. <i>JHEP Reports</i> , 2022, 4, 100411.	2.6	24
1184	Serum <i>Wisteria floribunda</i> α -glucuronidase-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	0.8	2
1185	Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: A Review of Links and Risks. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 457-465.	1.0	11
1186	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021, 61, 98-105.	1.7	15
1187	Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. <i>European Endocrinology</i> , 2021, 17, 112.	0.8	1
1188	Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. <i>Journal of Biomedical Informatics</i> , 2022, 126, 103986.	2.5	7
1189	Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000798.	1.1	3
1190	Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. <i>Metabolism Open</i> , 2022, 13, 100158.	1.4	8
1191	Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout. <i>Medical Science Monitor</i> , 2020, 26, e926187.	0.5	2
1192	Cardiovascular risk factors in patients with NAFLD and its relationship with the gut microbiota. <i>Ukrainian Therapeutical Journal</i> , 2020, .	0.0	0
1193	An Overview on Diagnosis and Management of Non-alcoholic Fatty Liver Disease. <i>International Journal of Pharmaceutical Research and Allied Sciences</i> , 2021, 10, 144-148.	0.1	0
1194	An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. <i>Diabetic Medicine</i> , 2022, 39, e14799.	1.2	8
1195	NFI, a clinical scoring tool for predicting non-alcoholic fatty liver in the Chinese population. <i>Public Health</i> , 2022, 202, 12-17.	1.4	3

#	ARTICLE	IF	CITATIONS
1196	Serum cadmium is associated with hepatic steatosis and fibrosis. <i>Medicine (United States)</i> , 2022, 101, e28559.	0.4	11
1197	Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5272-5279.	1.1	4
1198	Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. <i>Journal of Medical Economics</i> , 2022, 25, 347-355.	1.0	10
1199	A sequential approach using the age-adjusted fibrosis index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 994-1007.	1.9	2
1200	Switching to Regular Diet Partially Resolves Liver Fibrosis Induced by High-Fat, High-Cholesterol Diet in Mice. <i>Nutrients</i> , 2022, 14, 386.	1.7	2
1201	Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. <i>Journal of Clinical Medicine</i> , 2022, 11, 753.	1.0	4
1202	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	1.1	15
1203	Nonalcoholic fatty liver disease and type 2 diabetes: An update. <i>Journal of Diabetes Investigation</i> , 2022, 13, 930-940.	1.1	25
1204	Immune dysregulation in nonalcoholic steatohepatitis. , 2022, , 99-113.		0
1205	Research status and progress of metabolic associated fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2022, 30, 1-16.	0.0	0
1206	Liver-related and extrahepatic events in patients with nonalcoholic fatty liver disease: a retrospective competing risks analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 604-615.	1.9	18
1207	From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. <i>Biomedicines</i> , 2022, 10, 161.	1.4	4
1208	Metabolic dysfunction-associated fatty liver disease – How relevant is this to primary care physicians and diabetologists?. <i>Primary Care Diabetes</i> , 2022, , .	0.9	1
1209	Liver damage promotes proinflammatory T cell responses against apolipoprotein B100. <i>Journal of Internal Medicine</i> , 2022, 291, 648-664.	2.7	10
1210	Coagulation and Endothelial Dysfunction Associated with NAFLD: Current Status and Therapeutic Implications. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 339-355.	0.7	16
1211	PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice. <i>Scientific Reports</i> , 2022, 12, 483.	1.6	1
1212	Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by noninvasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 580-592.	1.9	12
1213	Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 3377-3387.	2.3	4

#	ARTICLE	IF	CITATIONS
1214	Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00435.	1.3	21
1215	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 370-379.	2.4	30
1216	Pharmacotherapeutic impact on nonalcoholic steatohepatitis histology: a systematic review and network meta-analysis. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, , .	0.4	4
1217	Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 280-282.	2.4	4
1218	2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 352-363.	1.8	8
1219	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.4	12
1220	Advances in fibrosis biomarkers in nonalcoholic fatty liver disease. <i>Advances in Clinical Chemistry</i> , 2022, 106, 33-65.	1.8	5
1221	Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. <i>Frontiers in Nutrition</i> , 2022, 9, 765206.	1.6	6
1222	2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2809-2817.e28.	2.4	255
1223	Adipose tissue. , 2022, , 209-228.		0
1224	Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. <i>Expert Review of Precision Medicine and Drug Development</i> , 2022, 7, 39-49.	0.4	0
1225	Predictive value of collagen in cancer. <i>Advances in Cancer Research</i> , 2022, 154, 15-45.	1.9	11
1226	The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 216-253.	0.2	19
1227	Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2668.	1.8	42
1228	Platelets in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 842636.	1.6	9
1229	Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2022, 11, 968.	1.0	20
1230	The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH). <i>International Journal of Molecular Sciences</i> , 2022, 23, 3562.	1.8	8
1231	Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. <i>Hepatology Communications</i> , 2022, 6, 1516-1526.	2.0	7

#	ARTICLE	IF	CITATIONS
1232	Probing the interaction of Selonsertib with human serum albumin: In silico and in vitro approaches. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, .	1.0	1
1233	Ultrasound Based Elastography Techniques for the Evaluation of Nonalcoholic Liver Disease. , 0, , .		1
1234	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (<sc>NAFLD</sc>). <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1441-1451.	1.9	9
1235	Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 603-616.	3.7	40
1236	Clinical Feasibility of Shear Wave Dispersion Slope for Noninvasive Diagnosis of Nonalcoholic Steatohepatitis in Patients With Morbid Obesity. <i>Ultrasound Quarterly</i> , 2022, Publish Ahead of Print, .	0.3	0
1237	Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3357.	1.8	3
1239	Repeated measurements of nonâ€invasive fibrosis tests to monitor the progression of nonâ€alcoholic fatty liver disease: A longâ€term followâ€up study. <i>Liver International</i> , 2022, 42, 1545-1556.	1.9	6
1240	Heparanase Inhibition Prevents Liver Steatosis in E0 Mice. <i>Journal of Clinical Medicine</i> , 2022, 11, 1672.	1.0	2
1241	The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population. <i>Scientific Reports</i> , 2022, 12, 5123.	1.6	2
1242	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 864570.	1.2	5
1243	Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102446.	1.8	3
1244	The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver. <i>Science Translational Medicine</i> , 2022, 14, eabe5795.	5.8	25
1245	Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. <i>European Journal of Internal Medicine</i> , 2022, 100, 77-82.	1.0	14
1246	Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. <i>Thrombosis Research</i> , 2022, 213, 9-15.	0.8	6
1247	Extracellular vesicle-mediated bidirectional communication between heart and other organs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2022, 322, H769-H784.	1.5	19
1248	Fibrosisâ€4 Index as an Independent Predictor of Mortality and Liverâ€Related Outcomes in NAFLD. <i>Hepatology Communications</i> , 2022, 6, 765-779.	2.0	26
1249	Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	0
1251	Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999â€2016. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2838-2847.e7.	2.4	38

#	ARTICLE	IF	CITATIONS
1252	Î2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. <i>Science Translational Medicine</i> , 2021, 13, eabk2267.	5.8	23
1253	The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease. <i>Biomedicines</i> , 2021, 9, 1853.	1.4	12
1254	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 12-22.	0.1	2
1255	Endoscopic sleeve gastropasty — minimally invasive treatment for non-alcoholic fatty liver disease and obesity. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 572-579.	0.7	14
1256	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Eating and Weight Disorders</i> , 2022, 27, 1603-1619.	1.2	9
1257	Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2008-e2020.	1.8	27
1258	Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 101161ATV00000000000000153.	1.1	167
1259	Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. <i>Hepatology</i> , 2023, 77, 230-238.	3.6	45
1260	Paediatric non-alcoholic fatty liver disease: an approach to pathological evaluation. <i>Journal of Clinical Pathology</i> , 2022, 75, 443-451.	1.0	4
1261	Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria. <i>Frontiers in Medicine</i> , 2022, 9, 869190.	1.2	8
1262	Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease. <i>Anesthesia and Analgesia</i> , 2022, 135, 957-966.	1.1	2
1263	Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes. <i>BMC Health Services Research</i> , 2022, 22, 487.	0.9	2
1264	The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 552-559.	3.7	25
1265	Nonalcoholic fatty liver disease and its prognosis associates with shorter leucocyte telomeres in a 21-year follow-up study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 173-180.	0.6	5
1266	Risk of cardiovascular disease and loss in life expectancy in NAFLD. <i>Hepatology</i> , 2022, 76, 1495-1505.	3.6	26
1267	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. <i>Journal of Hepatology</i> , 2022, 77, 607-618.	1.8	79
1268	Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center. <i>Journal of Clinical Medicine</i> , 2022, 11, 2271.	1.0	0
1273	Liver Fibrosisâ€4 index indicates atrial fibrillation in acute ischemic stroke. <i>European Journal of Neurology</i> , 2022, 29, 2283-2288.	1.7	5

#	ARTICLE	IF	CITATIONS
1274	Chlorogenic acid alleviated liver fibrosis in methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice and its mechanism. <i>Journal of Nutritional Biochemistry</i> , 2022, 106, 109020.	1.9	21
1275	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 755-769.	3.7	34
1276	Steatohepatitises: etiological variants, principles of diagnosis and management. <i>Meditinskiy Sovet</i> , 2022, , 74-82.	0.1	2
1277	Indications and methods for measuring portal hypertension in cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1149-1157.	0.6	2
1278	Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 931-939.e5.	2.4	42
1280	Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5146.	1.8	22
1281	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	1.1	323
1282	Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. <i>Current Atherosclerosis Reports</i> , 2022, 24, 533-546.	2.0	19
1283	Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis. <i>Antioxidants</i> , 2022, 11, 867.	2.2	6
1284	Metabolic syndrome and alcohol consumption as risk factors for liver disease: which border?. <i>Minerva Medica</i> , 2022, 113, 223-225.	0.3	1
1285	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	2.0	17
1286	Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. <i>Magnetic Resonance in Medical Sciences</i> , 2023, 22, 435-445.	1.1	2
1287	Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210982.	1.4	2
1288	Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210835.	1.1	2
1289	Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>World Journal of Hepatology</i> , 2022, 14, 1026-1038.	0.8	0
1290	Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. <i>PLoS ONE</i> , 2022, 17, e0266965.	1.1	4
1291	Non-alcoholic fatty liver disease- correlation between shear wave elastography and nafld fibrosis score: a descriptive single centre study. <i>International Journal of Research in Medical Sciences</i> , 2022, 10, 1271.	0.0	0
1292	Non-Invasive Liver Fibrosis Scores Are Associated With Contrast-Associated Acute Kidney Injury in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>Angiology</i> , 2023, 74, 333-343.	0.8	5

#	ARTICLE	IF	CITATIONS
1293	Clinical Phenotyping and the Application of Precision Medicine in MAFLD. <i>Clinical Liver Disease</i> , 2022, 19, 227-233.	1.0	3
1294	Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. <i>World Journal of Hepatology</i> , 2022, 14, 1025-1037.	0.8	7
1295	Differential Effects of Dietary versus Exercise Intervention on Intrahepatic MAIT Cells and Histological Features of NAFLD. <i>Nutrients</i> , 2022, 14, 2198.	1.7	10
1296	Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. <i>Cureus</i> , 2022, , .	0.2	7
1297	Unique Cardiovascular Disease Risk Factors in Hispanic Individuals. <i>Current Cardiovascular Risk Reports</i> , 2022, 16, 53-61.	0.8	7
1298	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	0.9	12
1299	The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease. <i>Multidisciplinary Cardiovascular Annals</i> , 2022, 13, .	0.2	0
1300	Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 477-496.	1.8	13
1301	Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis. <i>Neoplasia</i> , 2022, 30, 100809.	2.3	18
1302	Fatty Liver Disease. , 2022, , 265-298.		0
1304	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> , 2022, 23, .	3.1	7
1305	Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6696.	1.8	24
1306	The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. <i>JHEP Reports</i> , 2022, 4, 100525.	2.6	23
1307	Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits. <i>Journal of Hepatology</i> , 2022, 77, 1136-1160.	1.8	136
1308	When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. <i>Journal of Clinical Medicine</i> , 2022, 11, 3286.	1.0	8
1309	Liver stiffness accuracy by MR elastography in histologically proven non-alcoholic fatty liver disease patients: a Spanish cohort. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	1
1310	The practical utility of non-invasive indices in metabolic hepatic steatosis. <i>Endocrinología Y Nutrición (English Ed)</i> , 2022, 69, 418-425.	0.1	3
1311	Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH. <i>Journal of Hepatology</i> , 2022, 77, 1399-1409.	1.8	41

#	ARTICLE	IF	CITATIONS
1312	Agreement and accuracy of shear-wave techniques (point shear-wave elastography and 2D-shear-wave) Tj ETQq0 0 0 rgBT /Overlock 10 Hepatology, 2022, 34, 873-881.	0.8	3
1313	The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Clinical Nutrition, 2022, 41, 1913-1931.	2.3	50
1314	Non-alcoholic fatty liver disease-related fibrosis and sarcopenia: An altered liver-muscle crosstalk leading to increased mortality risk. Ageing Research Reviews, 2022, 80, 101696.	5.0	19
1315	Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study. Hepatology International, 2022, 16, 1035-1051.	1.9	4
1316	Current treatment of non-alcoholic fatty liver disease. Journal of Internal Medicine, 2022, 292, 190-204.	2.7	56
1317	The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. Frontiers in Pharmacology, 0, 13, .	1.6	11
1318	Does Fatty Liver Play a Role in the Risk of All-Cause and Cause-Specific Mortality in Patients with Gallstone Disease?. Clinical Gastroenterology and Hepatology, 2022, , .	2.4	0
1319	Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. Hepatology, 2023, 77, 573-584.	3.6	18
1320	Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology, 2022, 163, 1079-1089.e5.	0.6	52
1321	Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	7
1322	Nonalcoholic steatohepatitis medical patient journey from the perspective of hepatologists, gastroenterologists and patients: a cross-sectional survey. BMC Gastroenterology, 2022, 22, .	0.8	4
1323	Fibrosis-4 Index Is Closely Associated with Arterial Damage and Future Risk of Coronary Heart Disease in Type 2 Diabetes. International Journal of Hypertension, 2022, 2022, 1-8.	0.5	2
1324	Abdominal aortic calcification is associated with Fibrosis-4 index and low body mass index in type-2 diabetes patients: A retrospective cross-sectional study. Journal of Diabetes Investigation, 2022, 13, 1861-1872.	1.1	1
1325	Reversal of obesity development in <i>Ceacam1</i> male mice by bone marrow transplantation or introduction of the human <i>CEACAM1</i> gene. Obesity, 2022, 30, 1351-1356.	1.5	4
1326	Combination Therapies for Nonalcoholic Fatty Liver Disease. Journal of Personalized Medicine, 2022, 12, 1166.	1.1	18
1327	Phloridzin Reveals New Treatment Strategies for Liver Fibrosis. Pharmaceuticals, 2022, 15, 896.	1.7	6
1328	Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 8229.	1.8	3
1329	Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 8307.	1.8	9

#	ARTICLE	IF	CITATIONS
1330	Advances in ultrasound elastography for nonalcoholic fatty liver disease. Choonpa Igaku, 2022, , .	0.0	0
1331	Regulation of Adipose Thermogenesis and its Critical Role in Glucose and Lipid Metabolism. International Journal of Biological Sciences, 2022, 18, 4950-4962.	2.6	6
1332	Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. Journal of Clinical Medicine, 2022, 11, 4394.	1.0	3
1333	Alcohol use disorder identification test renamed Glu-Glu Test in an area of north-west of Italy: preliminary descriptive results. Minerva Gastroenterology, 2024, 69, .	0.3	4
1334	Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease. Endocrine Reviews, 2023, 44, 14-32.	8.9	32
1335	Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals. Scandinavian Journal of Gastroenterology, 2022, 57, 1478-1485.	0.6	2
1336	Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter. Diagnostics, 2022, 12, 1753.	1.3	4
1337	Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores. Nutrients, 2022, 14, 3163.	1.7	2
1338	European guideline on obesity care in patients with gastrointestinal and liver diseases â€œ Joint ESPEN/UEG guideline. Clinical Nutrition, 2022, , .	2.3	22
1339	Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Communityâ€œBased Cohort Study. Frontiers in Endocrinology, 0, 13, .	1.5	3
1340	The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scoresâ€œAn 11.6-Year Follow-Up Study. Journal of Clinical Medicine, 2022, 11, 4910.	1.0	5
1341	Evaluation of the feasibility of screening for paediatric nonâ€œalcoholic fatty liver disease. Acta Paediatrica, International Journal of Paediatrics, 2022, 111, 2408-2415.	0.7	6
1342	Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease. Abdominal Radiology, 2022, 47, 3733-3745.	1.0	4
1343	The association between non-alcoholic fatty liver disease (NAFLD) and advanced fibrosis with blood selenium level based on the NHANES 2017-2018. Annals of Medicine, 2022, 54, 2258-2267.	1.5	9
1344	Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. Journal of Hepatology, 2022, 77, 1482-1490.	1.8	37
1345	Gender Differences in Nonalcoholic Fatty Liver Disease. Euroasian Journal of Hepato-gastroenterology, 2022, 12, S19-S25.	0.1	5
1346	A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis. Cell Metabolism, 2022, 34, 1377-1393.e8.	7.2	12
1347	Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatology International, 2022, 16, 1412-1423.	1.9	10

#	ARTICLE	IF	CITATIONS
1348	Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model. World Journal of Gastroenterology, 2022, 28, 4620-4634.	1.4	0
1349	Simple diagnostic algorithm identifying at-risk nonalcoholic fatty liver disease patients needing specialty referral within the United States. World Journal of Hepatology, 2022, 14, 1598-1607.	0.8	1
1350	Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	19
1351	Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2839-2847.	1.1	3
1352	Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis. Expert Review of Endocrinology and Metabolism, 2022, 17, 425-434.	1.2	17
1353	Aspartate aminotransferase to alanine aminotransferase ratio and clinical outcomes after acute ischemic stroke: the CNSR-III registry. Internal and Emergency Medicine, 2022, 17, 1987-1996.	1.0	2
1354	European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterology Journal, 2022, 10, 663-720.	1.6	18
1355	Vibration-controlled Transient Elastography in NAFLD: Review Study. Euroasian Journal of Hepato-gastroenterology, 2022, 12, S41-S45.	0.1	1
1356	A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports, 2023, 5, 100563.	2.6	15
1357	Pathophysiologie: Insulinresistenz. , 2022, , 51-62.		0
1358	Hepatitis C and NAFLD as Main Causes of Liver-Related Morbidity and Mortality in the French General Population: A Nationwide Study (NASH-CO Study). SSRN Electronic Journal, 0, , .	0.4	0
1359	Association between hypothyroidism and liver fibrosis risk: a systematic review and meta-analysis. Clinical and Experimental Hepatology, 2022, 8, 188-194.	0.6	3
1360	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography. Choonpa Igaku, 2022, 49, 385-396.	0.0	0
1361	Diagnostik: Blutbasierte Marker. , 2022, , 149-155.		0
1362	Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study. Nutricion Hospitalaria, 2022, , .	0.2	2
1363	NatÄ¼rlicher Verlauf. , 2022, , 11-19.		0
1364	ACCURACY OF ELASTOGRAPHY IN THE ASSESSMENT OF REDUCTION IN LIVER STEATOSIS AND FIBROSIS IN THE EARLY POSTOPERATIVE PERIOD AFTER BARIATRIC SURGERY. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 0, 35, .	0.5	1
1365	Hepatic Fibrosis Is a Risk Factor for Greater Severity and Worse Outcome of Acute Ischemic Stroke. Journal of Clinical Medicine, 2022, 11, 5141.	1.0	2

#	ARTICLE	IF	CITATIONS
1366	Clinical and Metabolic Characteristics of Hyperuricemia with Risk of Liver Fibrosis: A Cross-Sectional Study. <i>Metabolites</i> , 2022, 12, 893.	1.3	1
1367	Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes. <i>Biomedicines</i> , 2022, 10, 2375.	1.4	5
1368	Increased risk of non-alcoholic fatty liver disease fibrosis is closely associated with osteoporosis in women but not in men with type 2 diabetes. <i>Endocrine Connections</i> , 2022, 11, .	0.8	6
1369	High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. <i>Hepatology Communications</i> , 2022, 6, 3212-3222.	2.0	3
1370	Advances in metformin for the treatment of non-alcoholic fatty liver disease in children. <i>Expert Review of Gastroenterology and Hepatology</i> , 0, , 1-15.	1.4	1
1372	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. <i>Hepatology</i> , 2023, 77, 1404-1427.	3.6	43
1373	Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. <i>Liver International</i> , 2023, 43, 90-99.	1.9	16
1374	Human Allogeneic Liver-Derived Progenitor Cells Significantly Improve NAFLD Activity Score and Fibrosis in Late-Stage NASH Animal Model. <i>Cells</i> , 2022, 11, 2854.	1.8	1
1375	Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2022, 101, e30527.	0.4	4
1376	Primary Care Providers and Nonalcoholic Fatty Liver Disease: A Needs Assessment Survey. <i>Digestive Diseases and Sciences</i> , 2023, 68, 434-438.	1.1	7
1377	Obesity and cancer-related extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 517-547.	2.7	9
1379	Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events. <i>Journal of Clinical Medicine</i> , 2022, 11, 5190.	1.0	3
1380	Differences in HDL-Bound Apolipoproteins in Patients With Advanced Liver Fibrosis Due to Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 108, 42-51.	1.8	3
1381	N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. <i>Hepatology International</i> , 2023, 17, 190-201.	1.9	6
1383	Incidence and Predictors of Liver-Related Events in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 37-47.	0.4	3
1384	Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. <i>Annals of Hepatology</i> , 2023, 28, 100769.	0.6	7
1385	Prevalence, characteristics, and mortality outcomes of obese and nonobese MAFLD in the United States. <i>Hepatology International</i> , 2023, 17, 225-236.	1.9	4
1386	Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity. <i>JHEP Reports</i> , 2023, 5, 100615.	2.6	5

#	ARTICLE	IF	CITATIONS
1387	A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease. <i>Endocrine Practice</i> , 2023, 29, 33-39.	1.1	9
1388	Approach to the Patient With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 483-495.	1.8	5
1389	Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 5969.	1.0	0
1390	Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies. <i>Diagnostics</i> , 2022, 12, 2608.	1.3	2
1391	Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	0
1392	Triglyceride: A mediator of the association between waist-to-height ratio and non-alcoholic fatty liver disease: A second analysis of a population-based study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
1393	Mouse models of nonalcoholic steatohepatitis and their application to new drug development. <i>Archives of Pharmacal Research</i> , 2022, 45, 761-794.	2.7	5
1394	Physical activity is inversely associated with hepatic fibro-inflammation: A population-based cohort study using UK Biobank data. <i>JHEP Reports</i> , 2023, 5, 100622.	2.6	4
1395	Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3829-3845.	2.0	8
1396	Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
1397	Quantitative imaging tests for non-alcoholic fatty liver disease: which, when and why. <i>Translational Gastroenterology and Hepatology</i> , 0, 8, 1-1.	1.5	1
1398	Non-alcoholic Fatty Liver Disease. In <i>Clinical Practice</i> , 2022, , 127-149.	0.1	0
1399	Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH). <i>International Journal of Molecular Sciences</i> , 2022, 23, 13501.	1.8	4
1400	Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from <scp>VERTIS CV</scp>, a randomized trial of the <scp>sodium-glucose cotransporter</scp> inhibitor ertugliflozin. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 758-766.	2.2	6
1401	Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and hepatic fibrosis in a prospective cohort. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2023, 14, 260-269.	2.9	4
1402	Hepatic fat as a novel marker for high-risk coronary atherosclerotic plaque features in familial hypercholesterolaemia. <i>Metabolism: Clinical and Experimental</i> , 2023, 139, 155370.	1.5	2
1403	Cardiac abnormalities in patients with nonalcoholic fatty liver disease. <i>Revista Da Associação Médica Brasileira</i> , 2022, 68, 1394-1399.	0.3	0
1404	Prediction of clinical events by liver stiffness and chronic kidney disease by NAFLD in patients with type-2 diabetes. <i>Gastroenterologã Y Hepatologã</i> , 2023, 46, 682-691.	0.2	1

#	ARTICLE	IF	CITATIONS
1405	Inhibition of 11 β -hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
1407	Clinical Trajectory and Predictors of Intensive Care Unit Mortality Among Nonalcoholic Fatty Liver Disease Patients: A Retrospective Caseâ€“Control Study. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 218-224.	0.4	2
1408	Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 102-111.	0.8	4
1409	Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	4
1410	Association of non-Alcoholic Fatty Liver Disease with Urolithiasis detected on non-Contrast Computed Tomography. , 2022, 7, 87-92.		0
1411	4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetesâ€“2023 </i>. <i>Diabetes Care</i> , 2023, 46, s49-s67.2.	4.3	58
1412	Pregnane X receptor gene variant rs7643645 and total mortality in subjects with nonalcoholic fatty liver disease. <i>Pharmacogenetics and Genomics</i> , 0, Publish Ahead of Print, .	0.7	1
1413	Adverse muscle composition is a significant risk factor for all-cause mortality in NAFLD. <i>JHEP Reports</i> , 2023, 5, 100663.	2.6	3
1414	Chronic kidney disease in nonalcoholic fatty liver disease at primary healthcare centers in Korea. <i>PLoS ONE</i> , 2022, 17, e0279367.	1.1	2
1415	Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study. <i>PLoS ONE</i> , 2022, 17, e0277729.	1.1	5
1416	Triglyceride to high-density lipoprotein cholesterol ratio is an independent predictor of liver fibrosis among pediatrics non-alcoholic fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
1417	A practical use of noninvasive tests in clinical practice to identify highâ€“risk patients with nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 304-312.	1.9	15
1418	Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers. <i>Journal of Physiology and Biochemistry</i> , 2023, 79, 851-868.	1.3	4
1419	Metabolic associated liver disease. <i>Panminerva Medica</i> , 2022, 64, .	0.2	1
1420	Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes. <i>Endocrine</i> , 2023, 80, 366-379.	1.1	6
1421	Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S171-S183.	4.5	4
1422	Identification of high-risk subjects in nonalcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S196-S206.	4.5	8
1423	The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study. <i>Diabetes Research and Clinical Practice</i> , 2022, 194, 110191.	1.1	4

#	ARTICLE	IF	CITATIONS
1424	Role of the Hippo pathway in liver regeneration and repair: recent advances. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	8
1425	Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 273-302.	0.4	16
1426	Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: A systematic analysis of the global burden of disease study 2019. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	12
1427	Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. <i>Annals of Hepatology</i> , 2023, 28, 100892.	0.6	2
1428	Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long-term mortality in acute myocardial infarction. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 1032-1044.	2.2	10
1429	Incidental finding of non-alcoholic steatohepatitis-cirrhosis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	0
1430	Positive Association Between the Chinese Visceral Adiposity Index and Nonalcoholic Fatty Liver Disease in Lean Adults. <i>Digestive Diseases and Sciences</i> , 2023, 68, 656-664.	1.1	2
1431	Diet Modulates Gut Microbiome and Metabolites in Non-alcoholic Fatty Liver Diseases. , 2023, , 131-146.		0
1432	Psychiatric Aspects of Obesity in Transplantation. , 2022, , 65-72.		0
1433	Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study. <i>Journal of Viral Hepatitis</i> , 0, , .	1.0	5
1434	Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X-Receptor agonist, in healthy volunteers. <i>Clinical and Translational Science</i> , 2023, 16, 536-547.	1.5	8
1435	Nonalcoholic Fatty Liver Disease Is Independently Associated With Higher All-Cause and Cause-Specific Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2588-2596.e3.	2.4	9
1437	Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2023, 324, E187-E198.	1.8	3
1438	The effect of acute and chronic exercise on hepatic lipid composition. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2023, 33, 550-568.	1.3	2
1439	Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
1440	CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. <i>Hepatology</i> , 2023, 77, 1241-1252.	3.6	9
1441	Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study. <i>BMJ Open</i> , 2023, 13, e063959.	0.8	0
1442	Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural. <i>Revista Colombiana De Gastroenterología</i> , 2022, 37, 420-433.	0.1	1

#	ARTICLE	IF	CITATIONS
1443	Non-alcoholic fatty liver disease: Definition and subtypes. <i>Clinical and Molecular Hepatology</i> , 2023, 29, S5-S16.	4.5	21
1445	Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	1
1446	The association between liver fibrosis scores and chronic kidney disease. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	1
1447	Preclinical and clinical evidence for the treatment of non-alcoholic fatty liver disease with soybean: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
1448	MAFLD: a multisystem disease. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2023, 14, 204201882211455.	1.4	28
1449	Evaluation of the effectiveness of the dioscorea in the treatment of patients with non-alcoholic fatty liver disease and dyslipidemia. <i>Meditinskiy Sovet</i> , 2023, , 156-161.	0.1	0
1451	Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
1452	Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 872-885.	1.9	6
1453	Epigenetics of NAFLD and NASH. , 2023, , 423-445.		0
1454	A natural history study of paediatric non-alcoholic fatty liver disease over 10 years. <i>JHEP Reports</i> , 2023, 5, 100685.	2.6	4
1455	Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: The Prognostic Role of Liver Stiffness Measurement. <i>Cancers</i> , 2023, 15, 637.	1.7	1
1456	Nonalcoholic fatty liver disease and cardiovascular disease. , 2023, , 11-16.		0
1457	Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 220-231.	1.8	9
1458	Emerging trends and hotspots in metabolic dysfunction-associated fatty liver disease (MAFLD) research from 2012 to 2021: A bibliometric analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	7
1459	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	3.6	358
1460	Diagnostic accuracy of ultrasound-guided attenuation parameter as a noninvasive test for steatosis in non-alcoholic fatty liver disease. <i>Choonpa Igaku</i> , 2023, , .	0.0	0
1461	Characterization of lipid composition and localization at different stages of nonalcoholic fatty liver disease using stimulated Raman scattering microscopy. , 2023, , .		1
1462	Screening for NAFLD—Current Knowledge and Challenges. <i>Metabolites</i> , 2023, 13, 536.	1.3	5

#	ARTICLE	IF	CITATIONS
1463	Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline. <i>Clinical Nutrition</i> , 2023, 42, 987-1024.	2.3	4
1464	Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 417-432.	4.5	4
1465	Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 373-395.	1.0	3
1466	The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases. <i>Medical Clinics of North America</i> , 2023, 107, 397-421.	1.1	2
1467	Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 239-250.	1.0	2
1468	Evaluation of fish meal replacement by <i>Clostridium autoethanogenum</i> protein in diets for juvenile red swamp crayfish (<i>Procambarus clarkii</i>). <i>Aquaculture</i> , 2023, 570, 739379.	1.7	3
1469	Association between liver fibrosis and decreased myocardial mechano-energetic efficiency in individuals with different degree of glucose tolerance. <i>Diabetes Research and Clinical Practice</i> , 2023, 199, 110639.	1.1	1
1470	Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease. <i>Clinics in Liver Disease</i> , 2023, 27, 353-362.	1.0	1
1471	A novel noninvasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD. <i>Journal of Viral Hepatitis</i> , 2023, 30, 287-296.	1.0	1
1472	The association between liver fibrosis and depression in patients after ischemic stroke. <i>BMC Neurology</i> , 2023, 23, .	0.8	0
1473	Prospective study of a case-finding algorithm to detect NAFLD with advanced fibrosis in primary care patients. <i>Hepatology Communications</i> , 2023, 7, e0024-e0024.	2.0	1
1474	Association between Cardiovascular Disease and Liver Disease, from a Clinically Pragmatic Perspective as a Cardiologist. <i>Nutrients</i> , 2023, 15, 748.	1.7	2
1475	Association of sarcopenia with liver fibrosis and steatohepatitis in non-alcoholic fatty liver disease: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2023, 13, e066181.	0.8	0
1476	Effect of pema fibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	6
1477	PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis. <i>Gastroenterology</i> , 2023, 164, 966-977.e17.	0.6	18
1478	Thyroid Hormone Receptor- β Agonists in NAFLD Therapy: Possibilities and Challenges. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2023, 108, 1602-1613.	1.8	8
1480	A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis. <i>Hepatology Communications</i> , 2023, 7, e0036-e0036.	2.0	2
1481	Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3563.	1.8	1

#	ARTICLE	IF	CITATIONS
1482	Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Medicina (Lithuania)</i> , 2023, 59, 375.	0.8	1
1483	Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes. <i>Gut and Liver</i> , 2023, 17, 610-619.	1.4	4
1485	Serum <sc>MFAP4</sc> , a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in <sc>NAFLD</sc> patients. <i>JGH Open</i> , 2023, 7, 197-203.	0.7	0
1486	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association. <i>Cardiology in Review</i> , 0, Publish Ahead of Print, .	0.6	1
1487	The Prevalence of Advanced Liver Fibrosis among Patients with Type 2 Diabetes Mellitus: A Single-Centre Experience in Penang, Malaysia. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , 2023, 38, 52-61.	0.1	1
1488	The use of current knowledge and nonâ€invasive testing modalities for predicting atâ€risk nonâ€alcoholic steatohepatitis and assessing fibrosis. <i>Liver International</i> , 2023, 43, 964-974.	1.9	8
1489	Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 459-468.	1.2	4
1490	Challenges and opportunities in NASH drug development. <i>Nature Medicine</i> , 2023, 29, 562-573.	15.2	51
1491	Novel urinary protein panels for the nonâ€invasive diagnosis of nonâ€alcoholic fatty liver disease and fibrosis stages. <i>Liver International</i> , 0, , .	1.9	1
1492	Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 1143-1150.	1.9	4
1493	CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1
1495	LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>Biomolecules</i> , 2023, 13, 560.	1.8	10
1496	Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and FibroscanÂ® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2023, 68, 2757-2767.	1.1	3
1497	Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Manâ€™s Land?. <i>Life</i> , 2023, 13, 857.	1.1	1
1498	Fibrosis score 4 index has an independent relationship with coronary artery diseases in patients with metabolic-associated fatty liver disease. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	1.2	4
1499	HÃgado graso (parte 2): enfoque clÃnico y tratamiento. <i>Revista Colombiana De Gastroenterologia</i> , 2023, 38, 46-58.	0.1	0
1501	Application of Scores Assessing Histological Activity and Estimated Long-Term Risk Analysis of Hepatic Decompensation of Non-Alcoholic Fatty Liver Disease in Individuals Undergoing Bariatric Surgery. <i>Obesity Surgery</i> , 0, , .	1.1	0
1502	Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0

#	ARTICLE	IF	CITATIONS
1503	Fatty Liver Disease. , 2024, , 330-401.		1
1505	Single-nucleus RNA sequencing of pre-malignant liver reveals disease-associated hepatocyte state with HCC prognostic potential. <i>Cell Genomics</i> , 2023, 3, 100301.	3.0	4
1506	Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	6
1507	Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease. <i>Hepatology International</i> , 2023, 17, 626-635.	1.9	2
1508	Non-alcoholic fatty liver disease is associated with a worse prognosis in patients with heart failure: A pool analysis. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
1509	Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
1510	Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH. <i>Hepatology</i> , 2023, 78, 1200-1208.	3.6	4
1511	Enhanced liver Fibrosis [®] test predicts liver-related outcomes in the general population. <i>JHEP Reports</i> , 2023, 5, 100765.	2.6	0
1541	<i>Endocrine</i> . , 2023, , 107-203.		0
1573	Friend or foe? The elusive role of hepatic stellate cells in liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 647-661.	8.2	11
1575	Natural History of Nonalcoholic Fatty Liver Disease. , 2023, , 19-43.		0
1576	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for Staging Nonalcoholic Fatty Liver Disease. , 2023, , 107-122.		0
1595	How non-alcoholic fatty liver disease and cirrhosis affect the heart. <i>Hepatology International</i> , 2023, 17, 1333-1349.	1.9	2
1636	Editorial: Liver hypercortisolism as a potential target for MASH treatmentâ€™Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 58, 1240-1241.	1.9	0
1659	NAFLD, the hepatic manifestation of the metabolic syndrome. , 2024, , 279-291.		0